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Abstract 
Streptococcus pyogenes is a human-specific pathogen that is responsible for serious 
morbidity and mortality worldwide despite being susceptible to common antibiotics. 
Furthermore, there is currently no licensed vaccine available against this organism. 
Previous research from our laboratory implicated a critical role for superantigens in a 
transgenic mouse model of acute nasopharyngeal infection by S. pyogenes. Herein, we are 
able to detect superantigen production in vivo and establish that anti-superantigen 
antibodies generated by either passive immunization or active vaccination with a major 
histocompatibility complex II-binding interface superantigen toxoid reduces S. pyogenes 
nasopharyngeal burden. We were also able to demonstrate that this organism requires 
responsive Vβ-specific T cells in order to efficiently infect the upper respiratory tract. 
These experiments remarkably reveal that S. pyogenes manipulates T cells to promote 
infection and also supports targeting superantigens as vaccine candidates to prevent 
nasopharyngeal carrier and subsequent disease caused by this globally important pathogen. 
Keywords 
Streptococcus pyogenes; superantigens; transgenic mouse model; nasopharyngeal 
infection; passive immunization; vaccination; T lymphocytes  
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 Introduction 
This thesis introduction will broadly outline what is known about S. pyogenes. It will first 
examine disease manifestations from a clinical perspective followed by descriptions of the 
best-studied virulence factors. Animal models of infection will then be discussed which 
will be concluded by current vaccine approaches against this organism. Emphasis should 
be paid to information regarding streptococcal SAgs and their role in infectious disease as 
well as limitations to current vaccine approaches. 
 Streptococcus pyogenes 
Streptococcus pyogenes (or Lancefield’s group A streptococci; GAS) is a Gram-positive, 
non-motile, non-sporeforming, aerotolerant anaerobic bacterium, generally round or ovoid 
and 0.5 to 1 µm in diameter. It grows in pairs or chains of varying length and when grown 
with blood, it exhibits β-hemolysis or complete lysis of red blood cells. The only known 
natural reservoir for this organism are humans, and it has been shown to colonize the skin, 
throat, vagina and rectum [1].  S. pyogenes is an important human pathogen capable of 
causing severe diseases such as necrotizing fasciitis and streptococcal toxic shock 
syndrome as well as mild illnesses such as pharyngitis or impetigo [2]. Individuals can also 
be asymptomatic carriers of the bacterium [3]. There are numerous post-infection, non-
suppurative sequelae caused by this organism including glomerulonephritis, acute 
rheumatic fever (ARF) and rheumatic heart disease (RHD) [2]. S. pyogenes bacteria remain 
susceptible to β-lactam antibiotics and there is currently no human-approved vaccine 
available. 
 Invasive streptococcal disease 
Invasive infections are defined as the isolation of the infecting organism from a normally 
sterile site. In regards to S. pyogenes, this includes invasion into deep tissues (such as the 
fascia [necrotizing fasciitis; NF] or the muscle [myositis]), bacteremia and streptococcal 
toxic shock syndrome (STSS). In 2005, it was documented that there were over 660,000 
new cases of invasive infections each year caused by S. pyogenes resulting in over 160,000 
deaths [4]. These were overwhelmingly in developing nations and thus it is thought that 
this number was an underrepresentation. Data from recent decades suggest that the 
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incidence and severity of invasive diseases has increased and this trend seems to be 
continuing [4–7]. 
NF is an infection of the underlying human subcutaneous tissue and fascia that results in 
inflammation and necrosis. It can be caused by numerous other organisms, but due to 
commonality and severity of tissue trauma, S. pyogenes has been termed the ‘flesh-eating 
bacteria’. Infection starts at an often trivial or sometimes benign site with minimal 
inflammation, but quickly worsens within the next 24-72 hours. A hallmark of NF is 
disproportionate pain to size of injury [8,9], which can help differentiate it from less severe 
tissue infections (impetigo, cellulitis), although differentiation is still difficult. Upon 
worsening, fever and severe pain become consistent, skin becomes ‘dusky’ and purplish, 
with edema occurring (filled with yellow or hemorrhagic fluid). These are all signs of the 
underlying necrosis, which spreads rapidly, and sloughing of the skin can be observed. 
Treatment consists of removal of infected tissue (debridement and pus drainage), 
antibiotics to treat the infection (β-lactams [penicillin] and/or protein synthesis inhibitors 
[clindamycin]), and aggressive supportive care (hemodynamic stabilization, nutritional 
supplementation and analgesic therapy) [2,10,11]. Mortality rates associated with NF are 
generally high, with case fatality rates reaching up to 50% in some settings [6,12–14]. 
STSS typically involves an invasive streptococcal infection associated with hypotension, 
shock and organ failure, and the clinical definition can be found in Table 1. Early 
symptoms may include pharyngitis, muscle pain, swollen lymph nodes and/or fever, 
followed by a sudden onset of vomiting, diarrhea, rash and hypotension. If symptoms 
persist, they may eventually result in multiple organ failure and potentially death. Unlike 
staphylococcal toxic shock syndrome (TSS), most STSS patients are bacteremic as well 
[15,16]. Mortality rates increase over NF and are generally between 30 and 70% [17–19]. 
Although the etiology of STSS is multifactorial, secreted toxins are thought to be 
significant contributors to the pathology [20]. Treatment of STSS is similar to NF and there 
is also evidence that administration of intravenous immunoglobulins (IVIG) can help 
reduce mortality by toxin neutralization [21,22]. 
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 Superficial and locally invasive infections 
S. pyogenes is known to cause numerous superficial skin and soft tissue infections. The 
most common are pharyngitis (commonly known as ‘strep throat’) and pyoderma, of which 
there were over 600 million and 100 million incidence cases per year, respectively, as of 
2005 [4]. It is possible that these infections may seed the severe and invasive diseases 
previously outlined, or result in post-infection sequelae as discussed below. While 
pharyngitis is widespread around the world, skin infections are much more common in 
resource poor settings due to inadequate hygiene and living conditions. 
‘Strep throat’ is the most common manifestation of S. pyogenes infection and is also the 
most common cause of bacterial pharyngitis. It constitutes between 20 to 40% of all 
pharyngitis cases in children and between 5 to 15% in adults [23,24]. Symptoms occur 
abruptly and may include: sore throat (pain described as severe), moderate fever (39°C to 
40.5°C), malaise, chills, headache, neck stiffness, and gastrointestinal symptoms (nausea, 
vomiting, abdominal pain). Examination of the throat reveals erythema and edema with 
purulent exudate forming on the tonsils. Cervical lymph nodes may become enlarged and 
tender. It is possible that fine erythematous papules become apparent on the trunk and 
spread towards the extremities with a sandpapery feel (scarlatiniform rash) and enlarged 
papillae may present on the tongue. These characteristics advance the diagnosis to ‘scarlet 
fever’, a similar, toxin-mediated illness associated with S. pyogenes [24]. These illnesses 
are self-limiting, and last around 8 to 10 days. However, due to the numerous potential 
complications associated with untreated S. pyogenes infections, antibiotic treatment is 
common which generally sees signs and symptoms subside within 24 to 48 hours.  
S. pyogenes is capable of causing numerous non-life threatening skin and soft tissue 
infections and classification is dependent upon which layer of the skin is involved. 
Infection of the superficial keratin layer (impetigo), the epidermis (erysipelas) and the 
subcutaneous tissue (cellulitis) are all possible. Impetigo manifests as a papule with a 
surrounding area of erythema. Pustules arise, breakdown and form a thick crust, heal 
slowly, and may leave depigmented areas. Since other common skin dwelling bacteria such 
as Staphylococcus aureus more commonly cause impetigo, and are penicillin resistant, it 
may be difficult to discern the causative agent and treat appropriately. An FDA approved  
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Table 1. Streptococcal toxic shock syndrome case definition 
  
I. Isolation of S. pyogenes from: 
Definite: Probable: 
Normally sterile site 
and 
Nonsterile site 
II. Hypotension 
and 
III. Two or more of the following: 
Renal impairment Coagulopathy 
Liver involvement General erythematous macular rash 
Tissue necrosis Respiratory distress 
From The Working Group on Severe Streptococcal Infections [19] 
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antibacterial, retapamulin, is also approved for treatment of methicillin-susceptible S. 
aureus and S. pyogenes impetigo [25]. 
Erysipelas is an infection of the dermis, but has lymphatic involvement. It is distinguishable 
by three features: the lesions are raised above the surrounding skin; a clear line of 
demarcation between involved and uninvolved skin; and a salmon-red colouring. Unlike 
impetigo, erysipelas is almost always caused by S. pyogenes. Upon infection, lesions begin 
to swell, become erythematic and become raised. If infection occurs on the face, it is 
common for eyes to become swollen shut. Chills and fever are also commonly associated. 
It is rare for infections to spread deeper and because a high proportion of cases are caused 
by S. pyogenes, penicillin is commonly used to treat these infections. 
Cellulitis occurs mainly from infections of burns, wounds, or surgical incisions. Symptoms 
include local pain, tenderness, swelling and erythema. There may be rapid spreading into 
the skin, and can contrast with erysipelas because lesions are not raised and demarcation 
between involved and uninvolved skin is indistinct. Fever, chills and malaise may be 
present, and bacterial spreading to lymphatics (lymphangitis), blood (bacteremia) or both 
is possible. Much like impetigo, it is hard to differentiate between cellulitis caused by S. 
pyogenes and S. aureus. Semi-synthetic penicillinase-resistant penicillin, cephalosporin, 
clindamycin, linezolid or vancomycin may be used to treat cellulitis, depending on the 
circumstances. 
 Asymptomatic Carriage 
Asymptomatic carriage is described as the presence of bacteria in the absence of signs or 
symptoms of infection. S. pyogenes is known to inhabit the human nasopharynx, genital 
mucosa, rectum, and skin in both pathogenic and benign instances. The majority of studies 
have studied asymptomatic colonization of the upper respiratory tract, and rates are 
typically around 12% for school aged children (5 to 18 years old) and much lower for adults 
and younger children [23,26]. Carriers do not seem to be at a higher rate of acquired 
immune disorders, and since they do not present with symptoms (coughing, coryza), they 
are found to be ineffective as transmitters. It is difficult to determine if carriers are more 
likely to have invasive infections because it is usually not possible to determine if a patient 
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was a carrier prior to an invasive infection. However, it has been shown that those suffering 
from invasive infections have close contacts that often contain S. pyogenes in the pharynx 
[27,28]. The asymptomatic carriage state of S. pyogenes remains an enigma and will 
probably remain so until more conclusive associations can be found. 
 Post-infection sequelae 
In 2005, it was estimated that S. pyogenes was associated with over 500,000 deaths each 
year due to severe and invasive diseases. From a morbidity and mortality standpoint, there 
were over 15.6 million cases of streptococcal post-infection sequelae per year and these 
resulted in the highest death rates (over 233,000 deaths per year) of all GAS-associated 
illnesses [4]. Streptococcal post-infection sequelae arise from molecular mimicry, whereby 
the host’s immune system not only generates a response against the invading organism, but 
also against self, due to bacterial factors that contain cross-reactive epitopes with human 
molecules. The two main molecules implicated in these types of diseases include the 
surface M protein and the group A carbohydrate (specifically, the dominant epitope of N-
acetyl-β-D-glucosamine) [29,30]. 
Acute rheumatic fever (ARF) is a delayed inflammatory illness that generally appears two 
weeks after S. pyogenes pharyngitis. ARF is diagnosed based on modified Jones Criteria 
(Table 2) in which an individual with evidence of preceding S. pyogenes infection (positive 
throat culture, positive rapid streptococcal antigen test or elevated anti-streptococcal 
antibodies) has a combination of two major manifestations, one major and two minor 
manifestations or three minor manifestations (depending on whether it was an initial or 
recurring ARF episode). Major criteria indicate the site of inflammation (heart, joints, 
brain, skin and/or subcutaneous tissue) and the minor criteria demonstrate clinical or 
laboratory findings (fever, joint pain [arthralgia], elevated acute phase reactants [increased 
erythrocyte sedimentation rate and C-reactive protein] and/or prolonged PR interval on an 
electrocardiogram). There are more than 470,000 cases of ARF each year and the majority 
are in children between the ages of 5 and 14 [4]. Most cases present in poor socioeconomic 
and developing nations and because of that, data are thought to be underrepresented. More 
specifically, rates are highest among Pacific populations, specifically those of aboriginal 
decent [31]. Repeated streptococcal infections and exacerbation of ARF can lead to  
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Table 2. Modified Jones criteria for diagnosis of acute rheumatic fever 
For all patient populations with evidence of preceding GAS infection 
Initial ARF 2 major manifestations OR 
1 major plus 2 minor manifestations 
Recurrent ARF 2 major manifestations OR 
1 major and 2 minor manifestations OR 
3 minor manifestations 
Major Criteria 
Low-risk populations* Moderate- and high-risk populations 
 Carditisǂ  Carditisǂ 
 Arthritis 
Polyarthritis only 
 Arthritis 
Mono- or polyarthritis 
Polyarthralgia 
 Chorea  Chorea 
 Erythema marginatum  Erythema marginatum 
 Subcutaneous nodules  Subcutaneous nodules 
Minor Criteria  
Low-risk populations* Moderate- and high-risk populations 
 Polyarthralgia†  Monoarthralgia† 
 Fever (≥38.5°C)  Fever (≥38°C) 
 ESR ≥60 mm in the first 
hour and/or CRP ≥3 mg/dL 
 ESR ≥30 mm/h and/or CRP ≥3 mg/dL 
 Prolonged PR interval‡  Prolonged PR interval‡ 
Adapted from Gewitz et. al. [32] 
GAS, group A Streptococcus; ARF, acute rheumatic fever; ESR, erythrocyte 
sedimentation rate; CRP, C-reactive protein 
*Low-risk population are those with incidence ≤2 per 100,000 school-aged children with 
ARF or all-age rheumatic heart disease prevalence of ≤1 per 1000 population per year 
ǂClinical (based on auscultation of typical murmurs) or subclinical (based on 
echocardiography) 
†Joint manifestations can only be considered in either the major or the minor categories 
but not both in the same patient 
‡Can only be used if carditis is not a major criterion 
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sustained damage of the heart. This clinical manifestation is known as rheumatic heart 
disease (RHD) and can involve any heart valve, but damage to the mitral and aortic valves 
are most common [4]. Determinants of progression are poorly understood and initial 
clinical presentation can range from asymptomatic valvular dysfunction to heart failure. 
The severity of the initial ARF case and recurrent S. pyogenes infections are known to be 
important factors in the progression of this disease [33] which can lead to other 
complications including infective endocarditis, atrial fibrillation and thrombolembolic 
stroke [34]. RHD is the number one cause of mortality associated with S. pyogenes 
infections. The Global Burden of Disease study recently indicated that there are 33 million 
prevalent cases of this disease, causing more than 275,000 deaths each year and more than 
9 million Disability-Adjusted Life Years (DALYs) lost [30,35–37]. 
Treatment for ARF is supportive, supplemented with antibiotics to treat infections and anti-
inflammatory medication. Secondary prophylaxis with antibiotics reduces the risk of RHD 
in patients with ARF and can also slow the progression and severity of disease in patients 
with established RHD [38,39]. In developed countries, surgical intervention of individuals 
with progressed RHD is also possible. 
Post-streptococcal glomerulonephritis (PSGN) is the most common cause of acute 
nephritis in children worldwide but can also occur in adults. It may typically occur after 
either pharyngitis (1 to 3 weeks) or impetigo (3 to 6 weeks) [40]. PSGN is thought to be 
due to inflammation as a result of deposition of complement component C3 and IgG in the 
kidneys. As of 2005, there were over 470,000 cases each year worldwide [4], mostly 
resulting from epidemics of impetigo in tropical countries [34]. Most common 
presentations of PSGN are haematuria and oedema with hypertension in around 60% of 
cases [41]. Full blown renal failure is rare, and death is seen in less than 1% of cases [4]. 
Usually, symptoms subside within 6-8 weeks without any treatment. 
 Group A Streptococcus Genome 
Based on 19 completed genomes, the 'core' of S. pyogenes genome is composed of a single, 
~1.8 Mbp circular chromosome with a G+C content of 38.5 ± 0.1%. There are 1,826 ± 92 
protein-coding regions, 5 or 6 rRNA operons, and 57 to 67 tRNA genes [42]. A major 
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source of genetic variability between strains is due to mobile (or putatively mobile) genetic 
elements including integrative conjugative elements (ICEs) as well as phage and phage-
like insertional sequences that generally harbor numerous virulence and adherence factors 
[43,44]. Many 'hallmark' virulence factors of S. pyogenes can be found on the ‘core’ 
genome including: M protein, the cysteine protease SpeB, the genes responsible for the 
production of the hyaluronic acid capsule and hemolysins, among numerous others. Genes 
on mobile genetic elements include DNases, antibiotic resistances and many of the 
streptococcal SAgs. 
 Streptococcal virulence factors 
1.7.1 M Protein 
The M protein is one of the best-studied surface molecules on Gram-positive organisms 
and is a major surface determinant present on S. pyogenes. The M protein plays a major 
role in virulence due to its ability to bind to numerous host factors (albumin, fibrinogen, 
factor H, IgG), preventing non-antibody mediated phagocytosis by PMN cells and 
mediating adherence to host tissues [29,45].   
The M protein is a multi-domain, alpha-helical coiled-coiled dimer that is anchored to the 
bacterial cell wall at the C-terminus through an LPXTG motif [29,46,47]. The 
hypervariable N-terminus of the M protein differs amongst strains and a region of about 50 
amino acids generates enough variability to aid in the classification of S. pyogenes. 
Serospecificity to this portion originally helped classify streptococci (known as M types); 
however, with the development of sequencing technology, a genetic classification system 
has been generated based on the nucleic acid sequence of this region (emm type) [48]. The 
genetic variability in this region has led to the discovery of over 200 emm types [49]. Based 
on the M6 protein – the ‘prototype’ M protein – the central region is made up of several, 
multiple repeat regions. Typically, the M protein is comprised of four repeat regions – 
designated A-D from the N- to the C-terminus – which make up the central helical rod of 
the M molecule. The upper A and B repeat regions are more variable between emm types 
with higher conservation in the C and D repeat regions. The C-terminus is composed of a 
mixture of positively and negatively charged amino acids, which are conserved amongst 
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many surface proteins. Just N-terminal of this is a hydrophobic core of around 15-22 amino 
acids (sufficient to span the cytoplasmic membrane) followed by the LPXTG consensus 
sequence. This sequence is recognized and cleaved by streptococcal sortase and 
incorporated into the cell wall.  
Other M proteins structures exist and they generally contain some, but not all of the 
aforementioned features. Thus, emm-typing is not as informative in regards to sequence, 
predicted structure or functional domains. A closely related typing method called emm 
pattern-typing distinguishes chromosomal architecture by taking into account the presence 
and arrangement of emm genes in the chromosome [50] with evidence that emm types 
correlate with emm patterns [51]. The emm patterns have been broken down into A-C 
pattern (e.g. M6), D pattern (e.g. M80) which lack the A repeats in the central helical 
domain, and the E pattern (e.g. M77) which lacks both A and B repeats. Although the best 
studied pattern is A-C, they account for approximately 20 percent of isolated organisms 
while other patterns account for approximately 75% [52]. 
Importantly, there have been associations of certain M types with disease phenotypes such 
as pharyngitis, impetigo and post-infection autoimmune sequelae [53–57]. This disease 
association with typing also stems to emm [13,14,58] and emm pattern-typing whereby the 
majority of pharyngitis isolates were found to associate with pattern A-C and impetigo 
isolates belonging to pattern D, whereas Pattern E was considered to be a ‘generalist’ group 
[44,52,59,60]. These data indicate the complexity of S. pyogenes classification, but also 
their importance in regards to disease association and potential implication in vaccine 
development. 
1.7.2 Capsule 
The capsule of S. pyogenes is composed of hyaluronic acid, a linear polymer of N-
acetylglucosamine and glucuronic acid. It is present on most, but not all clinical isolates in 
varying amounts and when present it gives the organism a mucoid colony morphology. 
The composition of the capsule is identical to hyaluronic acid found within the human host, 
which suggests that it may play a role in molecular mimicry and immune evasion. The 
capsule has been linked to virulence and it has been shown to increase resistance to 
12 
 
phagocytosis and aid in adherence to the pharynx by binding CD44 [61–64]. This is further 
demonstrated by the fact that hyper-encapsulated strains are frequently recovered from 
patients with invasive GAS infections [65]. The capsule is synthesized by the product of 
three genes that are found in the same operon and transcribed by the same promoter [66,67]. 
The hasA, hasB and hasC genes encode the hyaluronate synthase, UDP-glucose 
dehydrogenase and UDP-glucose pyrophosphorylase, respectively [68–71].  Interestingly, 
only hasA and hasB appears to be required for capsule expression [72]. These genes are 
regulated by the covRS (control of virulence; originally named capsule synthesis regulator 
[csr]) two component system [73]. A second regulator, rocA (regulator of Cov) was also 
shown to activate transcription of the repressor covR and thus has a negative impact on 
capsule production [74]. 
1.7.3 Streptococcal pyrogenic exotoxin B protease 
Streptococcal pyrogenic exotoxin B (SpeB) is a secreted cysteine proteinase that was 
originally thought to have pyrogenic and mitogenic activity [75], but this was later shown 
to be due to contamination. SpeB is produced in response to starvation during late log to 
early stationary phase in culture, as a 40 kDa inactive zymogen [76]. It then undergoes 
autocatalytic cleavage and conversion to a 28 kDa active enzyme [77]. Its proteinase 
activity is mediated by a cysteine at position 192 whereby upon mutation, the protein loses 
this function [78]. SpeB is known to cleave a number of host (vitronectin [79], fibronectin 
[79], IL-1β precursor [80], immunoglobulins [Ig] [81], complement 3 [82], chemokines 
CXCL 1-7, 10-14, 16 [83]) and bacterial (M protein [84], streptococcal mitogenic exotoxin 
Z [SmeZ] [85], streptokinase [86]) factors [87]. This overwhelming influence on the host 
and bacterium would suggest that this protease plays a key role in virulence. Essentially all 
clinical isolate strains encode speB [88] and in one study, over 84% of S. pyogenes strains 
demonstrated ‘wild-type’ SpeB activity (as assessed by casein hydrolysis assay) when 
compared to a reference strain [89]. However, the role of SpeB in pathogenesis is still not 
well defined. One study examining the invasive M1T1 isolate found that administration of 
a SpeB+ phenotypic strain into a subcutaneous murine chamber model resulted in a phase-
shift to SpeB-. Supernatants from SpeB- bacteria were also more immune stimulating than 
the parental SpeB+ strain [90]. But as mentioned above, the ability of SpeB to degrade 
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numerous host factors could play a beneficial role during infection. Expression of SpeB is 
highly regulated by the two-component system CovRS in which non-phosphorylated CovR 
represses the expression of speB [2,91]. It is likely that SpeB plays numerous roles during 
different types of infections and further research will be required to fully understand this 
cysteine protease. 
1.7.4 Streptococcus pyogenes cell envelope protease 
The S. pyogenes cell envelope protease (SpyCEP; ScpC) is capable of cleaving all human 
CXC chemokines that contain the ELR motif (including the neutrophil chemotractant IL-
8) [92–94]. SpyCEP is produced as a 170 kDa zymogen which undergoes autocatalytic 
cleavage to form two peptides which noncovalently link to form the active protease [92,95]. 
It can exist as either a secreted or cell-associated form and is produced throughout 
exponential growth [92,96]. Transcription is thought to be regulated by both the signaling 
peptide SilCR and the CovRS two-component regulatory system [97,98]. In vitro and in 
vivo models examining SpyCEP as a virulence factor are not completely conclusive, but it 
has been shown to mediate bacterial spread and impede clearance. Interestingly, expression 
of this molecule by Lactococcus lactis did produce hallmarks of streptococcal systemic 
infections [94,98–100]. To support the role of SpyCEP as a virulence factor, along with S. 
pyogenes, a number of other pathogenic streptococci also produce homologues of this 
protease [101].  
1.7.5 Streptococcal C5a peptidase 
The S. pyogenes C5a peptidase (ScpA) is a 130 kDa proteolytic enzyme that cleaves the 
complement-driven chemotaxin C5a at the PMN-binding site [102,103] which thus inhibits 
recruitment of phagocytic cells to the site of infection [103,104]. The scpA gene is 
controlled by the mga regulator [105,106] and the protein is bound to the bacterial cell 
surface by sortase A [107,108]. The importance of this molecule in bacterial fitness is 
supported by C5a peptidase homologues being found in Group B Streptococcus, which are 
thought to have arisen by horizontal gene transfer [109]. In mouse models of infection, 
bacterial strains without C5a peptidase were cleared more efficiently from an air sac model 
[104] and a nasopharyngeal infection model [110] compared to the wild-type strains. 
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1.7.6 Streptococcal inhibitor of complement-mediated lysis 
The streptococcal inhibitor of complement-mediated lysis (SIC) is a 31 kDa extracellular 
protein with multiple functions. SIC inhibits the formation of the membrane attack complex 
[111,112], inhibits the activity of antimicrobial peptide LL-37, and also inhibits the 
function of lysozyme, secretory leukocyte proteinase inhibitor and defensins [113–115], 
the chemokine MIG (CXCL9) [116] and interferes with the activation of the contact system 
of the innate immune response [117]. Evidence also exists that SIC may play a role in 
adhesion and colonization [118,119]. Interestingly, there is high variation in sic between 
GAS strains [114,120,121] which is thought to have arisen in response to host immune 
pressure during epidemics to enhance survival in vivo [122]. 
1.7.7 Hemolysins 
There are two major hemolysins secreted by S. pyogenes, Streptolysins O (SLO) and S 
(SLS). Both of these molecules have varying effects on a number of cell types. 
SLO is a 69 kDa cholesterol-dependent, thiol-activated, pore-forming cytotoxin that is also 
oxygen-labile. Pore formation in a host cell membrane occurs with binding of monomers 
in a cholesterol-dependent manner, in which there may also be glycan involvement. This 
is followed by oligomerization resulting in completion of the intact pore and can lead to 
apoptosis of the cell by disruption of membrane integrity [123–126]. SLO and another GAS 
product, NAD-glycohydrolase (S. pyogenes NAD-glycohydrolase [SPN]; encoded by the 
nga gene) are co-transcribed and it has been shown that SLO is required for the 
translocation of this molecule into host cells via a 70-residue N-terminal region on SLO. 
Inside the cell they act synergistically to trigger cell cytotoxicity [127]. Interestingly, 
cholesterol and pore formation are not required for this translocation [128–130]. SLO is 
thought to potentially play a role in barrier penetration, whereby SLO-mediated epithelial 
lysis allows toxin and bacteria to gain access to sub epithelial sites [131,132]. SLO has 
been shown to be an important virulence factor for GAS, as mutants lacking this molecule 
were less virulent in murine models [126,133,134]. The presence of SLO expression in 
human infections is supported by the fact that SLO is highly immunogenic and anti-SLO 
antibody titres are used as evidence of GAS infection [135,136]. 
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Streptolysin S (SLS) was first differentiated from SLO in 1938 by E. W. Todd, who also 
determined it was oxygen-stable (unlike SLO) and highly soluble in serum [137]. Later 
research would go on to show that a nine-gene operon (sagA-I) is responsible for the 
production of the 53 amino acid precursor (sagA), post-translational modification enzymes 
(sagB-D), immunity gene (sagE) and exporter (sagG-I) [138,139]. Each of these genes is 
required for expression of functional SLS, which is a 2.7 kDa, heterocyclic compound 
responsible for the β-hemolytic phenotype of GAS [140,141]. SLS cytolytic activity 
requires association with the bacterial cell surface or a carrier molecule [142,143] and is 
broad, including erythrocytes [137], leukocytes [144], platelets [145] and subcellular 
organelles [146,147]. SLS is related to class I bacteriocins [138] and cytolytic activity is 
thought to be similar to complement-mediated lysis, in which pore formation leads to 
osmotic lysis [148]. More recent research indicates a possible role for SLS in host cell 
signaling pathways at sub-lytic concentrations [149]. SLS is non-immunogenic, which is 
thought to be due to its post-translational modification and toxic effect on white blood cells 
[139]; however, neutralizing antibodies can be raised against synthetic peptide variants 
[150]. SLS was determined to be important in mouse models of GAS infection [151,152]; 
however, GAS strains with mutations in the SLS biosynthetic operon (non-hemolytic) have 
been shown to cause soft tissue infections, pharyngitis and otitis media [153,154]. 
1.7.8 Streptokinase 
Streptokinase (Ska; encoded by the ska gene) is a 46 kDa, multi-domain protein that non-
enzymatically converts the inactive zymogen plasminogen (Plg) to its proteolytically active 
form, plasmin (Plm) [155–157]. Conversion is thought to occur in a two-cycle pathway: 
(1) Trigger cycle - binding of Ska to Plg induces a conformational change in Plg resulting 
in the formation of an active site in the complex, where cleavage of Plg to Plm occurs. (2) 
Bullet cycle – Ska-Plm complex can bind a second Plg molecule which is quickly 
converted to Plm. One of the Plm is removed and another Plg can be bound and the cycle 
continues [158–160]. Variants of this protein are secreted by Group A, C and G 
streptococci which have functional differences and can be subdivided into two categories 
[161–163]. The role of Ska during infection is thought to be that activation of Plg to Plm 
increases dissemination by degradation of host extracellular matrix proteins both directly 
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and indirectly [2,29]. Ska is regulated by the two-component systems CovRS and FasBCA 
[91,164–167] and can be cleaved by SpeB [86]. Transgenic mice expressing human 
plasminogen had higher mortality when infected with GAS and susceptibility was 
dependent on Ska expression [168]. A novel inhibitor that reduces Ska gene expression 
also proved protective in this model, implicating a role for Ska in GAS pathogenesis [169].  
1.7.9 Superantigens 
 General Introduction 
The term ‘superantigen’ was first coined by Philippa Marrack and John Kappler in 1989 
due to the strong and specific reactivity of this family of toxins with T cells bearing specific 
T cell receptor (TCR) variable-beta (Vβ) chains with little input from other variable 
elements [170]. These toxins, however, were previously known to have mitogenic effects 
towards lymphocytes [171] and were actually discovered in the 1920s by George and 
Gladys Dick as the causative agent in scarlet fever [172]. Following these landmark papers, 
there have been numerous advancements in the field of SAg research which have aided in 
our understanding of these toxins. These findings include the diverse number of SAgs 
encoded by numerous organisms, their mode of action and the role they play in many 
diseases. 
 Superantigen Diversity 
Superantigenic molecules can be found in both gram-positive and -negative bacteria as 
well as in viruses. By far the best studied SAgs are found in the human pathogens S. aureus 
and S. pyogenes, but these toxins can also be found in other streptococcal species, the 
bacterium Mycoplasma arthritidis [173] and Yersinia pseudotuberculosis [174] as well as 
rabies [175], mouse mammary tumor [176] and human endogenous retro- [177,178] 
viruses. Due to the vast knowledge of the staphylococcal and streptococcal SAgs our 
primary focus will be on those toxins.  
The staphylococcal SAg nomenclature is based on the ability of the toxin to also cause 
food poisoning (including emesis), and are thus described as staphylococcal enterotoxin 
(SE) or -like (SEl) molecules. The SE SAgs have been scientifically shown to induce 
emesis, whereas SEl toxins have similar tertiary structure but not been shown to have this 
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feature [179,180]. The exception to this is the SAg primarily implicated in menstrual toxic 
shock syndrome (TSS), TSS toxin-1 (TSST-1) [181]. Despite nomenclature being 
primarily based on emetic properties, all SEs, SEls and TSST-1 have the ability to activate 
T cells based on TCR Vβ specificity (with the exception of SEH, which targets the TCR 
Vα chain [182–184]). Another group of related toxins, termed the staphylococcal 
superantigen-like proteins (SSLs; originally named staphylococcal enterotoxin-like [SET] 
proteins) were shown to have high sequence similarity to the staphylococcal SAgs but were 
not enterotoxic or superantigenic [179,185,186]. There are currently over 20 
staphylococcal SAgs and with genomes being ‘mined’ for these toxins, more are likely to 
be discovered. 
Streptococcal SAgs were first named due to their ability to induce fever (e.g. streptococcal 
pyrogenic exotoxin [Spe]) and later based on their mitogenic (streptococcal mitogenic 
exotoxin [Sme]) or superantigenic (streptococcal SAg [SSA]) activities. Upon the 
screening of numerous streptococcal genomes (including Group A, C and G streptococci) 
an abundance of streptococcal SAgs and numerous alleles were discovered and 
subsequently characterized and named. Despite sequences being extremely similar (or the 
same), numerous toxins were differentially named, which caused confusion in the field of 
streptococcal SAg research for years. Recently, Commons et al. analyzed the literature and 
clarified a number of these errors [187]. This clarification has led to the classification of 
14 streptococcal SAgs, SpeA, C, G, H, I, J, K, L, M, N, O, P, SSA and SmeZ, of which 11 
are found in GAS (all except SpeN, O and P). There is also allelic diversity within specific 
SAgs in which 91 unique nucleotide sequences encoding complete streptococcal SAgs 
were found to belong to those 14 SAgs mentioned above. By far the greatest allelic 
diversity was discovered in SmeZ which had over 50 variants, some of which were 
nonfunctional due to a single base pair deletion forming a truncated protein [187–189]. 
Between the staphylococcal and the streptococcal SAgs, a family of toxins (termed the SAg 
superfamily) with highly conserved tertiary structure and apparent functional redundancy 
has been described [179,190]. The SAgs produced by these organisms can be categorized 
into five groups (Group I – V) based on their amino acid sequences. Interestingly, SAgs 
generally do not cluster based on the organism that produces them, indicating potential 
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horizontal gene transfer between organisms throughout their evolution. TSST-1, the non-
emetic, causative agent of menstrual staphylococcal TSS [191], and SEl-X are the only 
SAgs in Group I [192]. Group II SAgs include common causes of non-menstrual TSS such 
as SEB, SEC [193,194] and SpeA [17]. Group III contains only staphylococcal SAgs such 
as SEA, SED and SEE, all of which are known to be emetic [195]. Group IV SAgs are all 
from streptococcal species and include the well-studied SpeC. Group V consists of mostly 
staphylococcal SAgs from the SEl group, other than SEI and SpeI. The differences between 
SAg Groups I – V are not only their amino acid sequences, but also the engagement of host 
immune receptors, which will be discussed below. 
The majority of staphylococcal and streptococcal SAgs are found on mobile genetic 
elements. The staphylococcal SAgs are generally found on prophages, plasmids and 
pathogenicity islands (PI), discrete chromosomal accessory genetic segments harboring 
many virulence factors, but lacking essential genes [196–198]. The same is observed with 
streptococcal SAgs in that they are primarily found on phage-like elements [43,199]. In 
both organisms, however, there are SAgs encoded on the core genome, such as selx in S. 
aureus [200] and speg, spej and smez in S. pyogenes [199]. The presence of SAgs on mobile 
genetic elements would suggest the possibility of SAg gene movement between organisms. 
This has indeed been shown with streptococcal species in which SAgs on a lysogenic phage 
were transferred between GAS strains [201] and even to GCS [202]. These results support 
the idea of horizontal transfer of SAg genes between species, contributing to their 
evolution, as well as incorporation of these toxins into the core genome if the bacteria stand 
to benefit. 
 Superantigen structure and binding to host immune receptors 
Numerous crystal structures of SAgs, either alone or in complex with immune components 
have been solved and have aided in our understanding of SAg interactions. For the purpose 
of this introduction, we will focus primarily on streptococcal SAgs. The crystal structures 
of SpeA [203], SpeC [204], SpeH [205], SpeI [206], SpeJ [207] and SmeZ [205] have all 
been solved, and for those that have not, structural modeling can be done using previously 
crystalized SAgs as a scaffold backbone. 
19 
 
The immune-stimulating properties of SAgs stems from their simultaneous interaction with 
the host MHC II molecules on the surface of antigen presenting cells (APCs) and TCR Vβ 
chains. The classical SAg structure (which pertains to most streptococcal and 
staphylococcal SAgs) consists of a protoxin with a secretion signal that is cleaved from the 
N-terminus upon export via the general Sec-dependent secretory pathway. The mature 
exotoxin is between 22 – 29 kDa and is stated to be highly resistant to heat, acidity and 
desiccation. More specifically, all classical SAgs from S. aureus and S. pyogenes follow a 
similar tertiary structure, in which the N-terminus contains a mixed β-barrel domain with 
Greek key topology also known as an oligonucleotide/oligosaccharide-binding (OB) fold. 
This domain binds the major histocompatibility complex (MHC) class II -chain in a low-
affinity interaction and the TCR. The C-terminus is a β-grasp fold and contains a twisted 
β-sheet capped by a central α4-helix. This β-grasp fold contains the zinc-dependent, high-
affinity MHC binding interface for SAgs in Groups III – V. A section of the N-terminus 
also extends over the top of the C-terminus packing against a four-strand antiparallel 
twisted sheet resulting in a tight architecture which likely makes these molecules resistant 
to the conditions stated above (Figure 1A). Residues from this area are also involved in 
TCR interactions. The overall architecture varies slightly between SAgs, which explains 
their preference for certain TCR Vβ chains and MHC II interactions. 
Binding of the TCR and the MHC II by SAgs differs significantly from conventional T cell 
activation (Figure 1B) and can be generally categorized based on Groups I – V. What is 
generally understood with TCR Vβ interaction is that binding of the complementarity-
determining region (CDR) 2 loop appears to be a requirement for all staphylococcal and 
streptococcal SAgs and governs TCR Vβ-specificity, whereas other binding sites in the Vβ 
domain are responsible for stabilizing the interaction [208]. TSST-1, a Group I SAg, 
uniquely binds the MHC α-chain through a peptide-dependent, N-terminal low-affinity 
binding domain [209,210] and the TCR Vβ chain CDR2 region as well as the third 
framework (FR) region, in an energetically cooperative manner [208,211,212] (Figure 
1C). Group II SAgs – including SpeA, SEB, SpeH and SSA – bind the MHC II α-chain 
through a peptide-independent, low-affinity, N-terminal site [213] and the TCR Vβ chain 
through conformational dependent mechanisms (largely independent of specific Vβ amino  
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Figure 1. Superantigen structure and immune complex formation. 
A. Ribbon diagram of the superantigen (SAg) SpeC (PDB: 1HQR) [204] with colour-
highlighted immune interaction domains. N- to C-terminus: T cell receptor (TCR; blue), 
low-affinity MHC class II (yellow), linking central α-helix (green) and zinc (cyan)-
dependent high-affinity (red) MHC class II interacting domains. B. Conventional TCR (α-
chain, blue; β-chain, yellow) recognition of a peptide (black) in complex with MHC class 
II (α-chain, red; β-chain, green) (PDB: 1FYT) [214]. C – G. Binding of TCR and MHC 
class II by representative SAgs from Groups I – V built on the backbone of SEB/MHC/TCR 
(PDB: 4C56) [215]. C. TSST-1 interacting with human TCR Vβ 2.1 (PDB: 2IJ0) [211] and 
HLA-DR1 MHC class II [209]. D. SEB interaction with TCR Vβ19 and HLA-DR1 (PDB: 
4C56) [215]. E. SEH high-affinity MHC class II interaction with HLA-DR1 (PDB: 1HXY) 
[216] and TCR Vα27 (PDB: 2XNA) [183]. F. SpeC interaction with high-affinity MHC 
class II HLA-DR2a (PDB: 1HQR) [204] and human TCR Vβ2.1 (PDB: 1KTK) [217]. G. 
SEK interaction with human TCR Vβ5.1 (PDB: 2NTS) and MHC class II high-affinity 
interaction site based off of SEI bound with HLA-DR1 (PDB: 2G9H) [218]. 
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acids side chains) restricted to CDR2 and hypervariable (HV) region 4 [217,219,220] 
(Figure 1D). Group III contains only S. aureus SAgs (such as SEA, SEE and SEH) and 
these SAgs bind MHC II with both the low- and high-affinity interactions [216,221–223]. 
Along with the crystal structure of SEH in complex with a TCR Vα chain [182,183] 
(Figure 1E), two other Group III SAgs have been recently crystalized with TCR Vβ to 
help define this interaction. SEA and SEE have highly similar amino acid sequences, 
structures and TCR Vβ interacting interfaces. A shallow groove in the SAg interacts mainly 
with the CDR2, FR3 and HV4 and to a lesser extent the CDR1 and FR4 regions of the TCR 
Vβ [224,225]. The Group IV SAgs are all produced by streptococci and include the well-
studied SpeC. Like Group III SAgs, these toxins also contain a high-affinity MHC binding 
domain [204]. Our laboratory has also outlined a low-affinity binding site for SpeC, which 
acts similarly to the Group II SAgs [226]. Mutation of the SpeC high-affinity MHC-binding 
site via amino acid replacement of crucial zinc-binding residues (aspartic acid at position 
203) significantly reduces, but does not extinguish, immune activation [227]. SpeC 
engagement of the TCR is highly specific for human TCR Vβ2.1 in that it engages all 
hypervariable loops (CDR 1 – 3 and HV4). There are single residue insertions in the CDR 
1 and 2 loops of the human TCR Vβ2 which SpeC makes extensive networks of 
intermolecular contacts with [217], which are energetically and functionally important for 
this interaction [228] (Figure 1F). Lastly, Group V SAgs include mostly staphylococcal 
SAgs (such as SEl-K and SEI) and SpeI. The best characterization of a Group V SAg and 
MHC is that of SEI with HLA-DR1 in which binding occurs similarly to Group IV SAgs 
[218]. Probably the most unique feature of this SAg group is the existence of an additional 
~15 amino acid loop between the third α-helix and the eighth β-sheet (α3-β8 loop) that has 
been shown to be crucial for T cell activation [206]. For SEl-K, this loop has a recognition 
site on the apical loop of the human TCR Vβ5.1 FR4 that is necessary for binding and 
required for functional activation of this T cell subset [229] (Figure 1G). 
Another important consideration is the specificity of the SAg-TCR interaction. If a SAg 
targets a variety of TCR Vβ chains, then it is considered to have less specific interactions, 
and if it targets only one TCR Vβ chain with high affinity then it is considered very specific. 
The least specific SAgs (including SEB and SEC) make hydrogen bonds with the main-
chain atoms of the TCR Vβ CDR2 and HV4 loops [219,220] (Figure 1D). Slightly higher 
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specificity exists for SpeA, in which it contacts more hypervariable loops than those 
mentioned previously and additional hydrogen bonds are formed between side-chain atoms 
from both TCR and SAg [217]. Upon further restriction of TCR Vβ interaction, the entire 
hypervariable portion of the TCR Vβ chain is engaged. The best described example would 
be SpeC, in which the Vβ it engages – human TCR Vβ2.1 – has non-canonical residue 
insertions that it also makes contacts with, providing a unique binding site [217] (Figure 
1F). The highest specificity is seen when SAgs make contacts with unique features within 
the CDRs and FRs of the TCR Vβ, such is the case with TSST-1 and SEl-K [211,229] 
(Figure 1C and 1G). 
The culmination of this work is that we can now use crystal structures to visualize the full 
ternary complex (MHC/SAg/TCR). In fact, SEB was recently crystalized in this complex 
demonstrating that the SAg adopts a wedge-like position allowing for interaction of the 
TCR α chain with the MHC, but preventing contact with the peptide so T cell activation is 
peptide-independent [215] (Figure 1D). Although crystal structures of actual full ternary 
complexes do not exist for other classical SAg groups (a ternary complex involving MAM 
has been published [230]), we can use molecular modeling to postulate what is likely 
occurring. TSST-1 (Group I) generates contact with MHC and TCR as described above, 
but unlike SEB, there is thought to be no interaction between MHC and TCR due to the 
relative orientation with the SAg/MHC and the SAg/TCR interactions (Figure 1C). The 
SAgs with high-affinity, zinc-dependent MHC binding sites (SpeC, Group IV [Figure 1F]; 
SEl-K, Group V [Figure 1G]) are thought to bridge TCR and MHC similar to TSST-1 in 
that there is no actual contacts made between MHC and TCR. SpeC, which also has a low-
affinity MHC site [226], is also able to bridge MHC/TCR similar to Group II (Figure 1F). 
The last consideration of this immune complex (SAg/MHC/TCR) formation is the 
energetic favorability of these interactions. The optimal affinity range of MHC/TCR 
interactions required for T cell activation is thought to be between between 10-7 to 10-5 M 
[231]. Although diverse, all of the above mentioned SAg/MHC/TCR interactions are able 
to achieve affinities within this range [206,228,232,233], allowing these toxins to potently 
activate T cells, which is the currently understood biological role of SAgs. 
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Recently, the classical view of SAg/MHC/TCR binding has been challenged by the 
potential interaction of SAgs with the co-stimulatory CD28 molecule [234]. CD28 is 
expressed on the T cell surface and  interacts with the B7 molecules CD80 and CD86 [235]. 
It was demonstrated that SEB binds CD28 with micromolar affinity and that this interaction 
was required for induction of proinflammatory cytokine genes and a structural model was 
also suggested with SEC [236]. A CD28 mimetic peptide was also shown to be protective 
in a murine lethal challenge model with SpeA and S. pyogenes infection [237]. A potential 
criticism of this model is that all data thus far have been derived from low-affinity MHC 
interacting SAgs, while the majority (9 of 11) of streptococcal SAgs also have a zinc-
dependent, high-affinity MHC binding interface. The suggested SAg-CD28 interface 
would sterically hinder this interaction, and thus it is unclear whether or not CD28 
interaction plays a role in immune-complex binding or if there is an alternative CD28 
binding site. 
 Cell signaling induced by superantigens 
SAgs activate far greater proportions of naïve T cells compared to classical antigen 
presentation due to their affinity for the MHC and specific TCR Vβ chains. Stimulation, as 
mentioned above, occurs by SAgs binding both the MHC II molecule on the surface of 
APCs and the TCR on T cells in a Vβ-dependent manner, resulting in extensive T cell 
clonal proliferation and activation. Individual SAgs bind different TCR Vβ repertoires that 
can be very specific for a single V, or more promiscuous leading to a characteristic 
‘fingerprint’ associated with that SAg. It is important to note, however, that research has 
also indicated TCR Vβ response can vary with stimulation strength, whereby a broader 
repertoire of Vβ-response can be seen at higher SAg concentrations or through presentation 
with an MHC molecule that binds with higher affinity [238]. Regardless, the consequence 
of this interaction is activation of the bound T cells and downstream signaling that results 
in the release of numerous cytokines into the local immune environment. SAgs have been 
shown to activate multiple T cell subsets including both CD4+ and CD8+ T cells [239], γδ 
T cells [240] and invariant natural killer T cells (iNKT) [241]; however, it is not known 
whether intracellular signaling in these subsets differs. By far, the best studied SAg-
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mediated T cell activation cell-signaling pathways has been in traditional αβ T cells, which 
is outlined below. 
Binding of SAgs to MHC and TCR are thought to induce a similar signaling cascade as 
normal antigen recognition. Upon interaction of the TCR/MHC (by a SAg), Lck (a src 
family protein tyrosine kinase associated with the cytoplasmic tail of the co-receptor 
molecules CD4/CD8) is thought to be dephosphorylated on a negative regulatory tyrosine 
(Y505) by CD45 upon recruitment of the co-receptor molecule to the TCR/CD3 complex. 
Lck then phosphorylates immunoreceptor tyrosine-based activation motifs (ITAMs) on the 
cytoplasmic tail of the CD3 complex, which becomes the site for the recruitment and 
activation of ZAP-70 (Syk family tyrosine kinase). Activated ZAP-70 phosphorylates 
tyrosine residues on the cytoplasmic portion of the transmembrane adaptor linker of 
activated T cells (LAT). This cascade leads to activation of phospholipase C (PLC)γ, which 
converts phosphatidylinositol 4,5-bisphosphate (PIP2) to the second messengers inositol 
triphosphate (IP3) and diacylglycerol (DAG). IP3 is responsible for increasing intracellular 
Ca2+ and DAG activates protein kinase C (PKC) and Ras. Intracellular Ca2+ drives 
calcineurin dephosphorylation of NFAT which allows translocation to the nucleus. DAG 
leads to activating of the Ras/Raf-1/MEK/ERK pathway which leads to transcription factor 
AP-1 (Fos/Jun) translocation to the nucleus. DAG also plays a role in PKC activation which 
eventually leads to NF-κB (Rel and p50) translocation to the nucleus and upregulation of 
gene transcription. A second Lck-independent signaling pathway was also shown to be 
present during SAg-mediated T cell activation. The G protein Gαq11 is thought to activate 
another phospholipase (PLCβ), which also cleaves PIP3 into IP3 and DAG which, in turn, 
would continue the cascade similarly from there. T cell activation drives upregulation of 
activation markers (such as the IL-2 receptor α-chain; CD25), adhesion molecules and 
induces expression of numerous cytokines. The induction of NFAT, AP-1 and NFκB drive 
the expression of proinflammatory cytokines such as IL-1, IL-2, IL-6, IFNγ and TNFα 
[242–245]. 
The response of T cells to SAgs can be separated into three distinct phases: (1) 
activation/proliferation, (2) deletion and (3) unresponsiveness/anergy [239,246]. The 
aforementioned signaling cascade results in T cell proliferation (cell division) and 
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activation (secretion of cytokines and chemokines). This is the first phase and lasts 
generally from the initial hours of exposure to around two days. The newly expanded T 
cell subset then undergoes rapid deletion (phase 2) [247–249]. The mechanism behind this 
sudden decrease in cell numbers is still not entirely clear, but it is thought to be due to 
Fas/FasL-mediated activation-induced cell death [250]. The last phase is a prolonged state 
(can last for months) of unresponsiveness termed ‘anergy’, whereby the cells that did not 
undergo deletion are still present, but they are unable to be restimulated by SAgs and other 
T cell mitogens (anti-CD3 antibodies, concavalin A, etc.) [251]. This state has been 
extensively studied in murine models of SAg-exposure [251–255] and has been shown in 
human lymphocytes [256]. Importantly, depletion of specific TCR Vβ T cell subsets has 
been observed in humans with streptococcal diseases [257,258], indicating that this 
phenomenon can occur during streptococcal disease manifestation. 
Although numerous cell types can act as APCs for the SAg/MHC/TCR ternary complex, 
the effect of different cell types as APCs remains poorly studied. It seems that SAg 
stimulation of APCs leads to a signaling cascade similar to that seen in traditional 
MHC/TCR interaction. This is similar to what was presented above whereby a tyrosine 
kinase (in this circumstance Syk) is phosphorylated upon immune complex interaction 
which results in intracellular Ca2+ increase due to PLC activation [259]. This has been 
shown to lead to cytokine expression in APCs as well including TNF, IL-6, IL-10 and IL12 
as well as an increase in numerous surface markers [260,261]. When the APC is a B cell, 
it has been shown that SAg interaction increases MHC mRNA [262] and non-specific, 
polyclonal Ig response [263]. It has also been demonstrated that different SAgs interact 
better with specific human MHC (HLA) molecules [264–266]. These data indicate that 
APCs play an important role during SAg immune stimulation, and that further work is 
needed to elucidate the differences between this diverse group of cells and the impact they 
may have in disease progression. 
 Superantigen disease associations 
Human evidence to support the involvement of SAgs in specific diseases generally comes 
in one of three forms: epidemiological studies showing an increase in proportion of disease 
associated with strains encoding specific SAg genes, serological studies detecting 
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seroconversion to SAgs, or TCR Vβ skewing patterns in patients that are associated with a 
specific SAg.  
The disease originally associated with SAgs was scarlet fever, which was first shown to be 
caused by erythrogenic toxins – later revealed to be SAgs – produced by GAS [172]. It is 
thought that the rash associated with scarlet fever is the result of immune stimulation by 
bacterial SAgs. Although no single toxin is consistently associated with scarlet fever, 
SpeA, SpeC and SSA seem to have the highest correlation with the disease, generally 
determined by PCR amplification of the SAg genes from patient-isolated strains [267–
270].  
The dysregulated immune response in STSS has led to the suggestion of SAg involvement 
for decades. A large majority of supporting evidence involves epidemiological data that 
has associated GAS serotypes encoding specific SAgs with cases of STSS. Primarily, speA 
and speC have been associated [270–276]; however, other groups have also found other 
SAgs (speJ, speK, speM and ssa) to be involved [277–280]. Despite this evidence, other 
analyses have reported no apparent difference in SAg gene frequencies between invasive 
and non-invasive S. pyogenes isolates [281–284]. One study was able to detect SpeA in the 
sera from two patients with STSS [285] and another study attributed SmeZ ( either alone 
or in combination with SpeJ) as the causative agent in STSS [20]. Lack of neutralizing 
antibodies has also been theorized to be a risk factor for STSS and other severe 
streptococcal disease. Eriksson et al. showed low anti-SAg antibody titres in patients with 
STSS and bacteremia compared with those from uncomplicated erysipelas [286], whereas 
Basma et al. showed higher neutralizing anti-SAg antibodies in those with both severe and 
non-severe invasive GAS disease compared to matched healthy donors [287]. Numerous 
studies have also detected the unique ‘fingerprint’ that SAgs leave on the TCR Vβ-
repertoire, matching SAgs present in isolates from GAS severe infections to proliferation 
or depletion in specific TCR Vβ subsets [257,258,288]. These data, although not entirely 
conclusive, do suggest that SAgs play a significant role during STSS and potentially other 
severe and invasive GAS infections in humans. 
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There is also support for a superantigenic role in Kawasaki Disease, a systemic vasculitis 
that affects young children (generally less than 5 years old) and can lead to coronary artery 
damage [289]. A number of studies have analyzed TCR Vβ-skewing patterns, anti-SAg 
antibody titres, and PCR analysis to detect SAg in stool samples from patients, all which 
suggest a role for SAgs in this disease [290–296]. Some groups, however, have failed to 
show evidence of SAg involvement with Kawasaki Disease. These findings are mainly 
associated with the lack of anti-SAg antibodies [297–299] or the fact that oligoclonal 
expansion of B cell IgM transcripts were detected in peripheral blood of patients with 
Kawasaki Disease, indicating disease pathogenesis from a conventional antigen and not a 
SAg [300]. The overall findings seem to support a role for SAgs in the disease pathogenesis 
of Kawasaki Disease, but with some conflicting results and no direct mechanism available, 
further research will have to be done to elucidate the role for these toxins in this disease. 
Guttate psoriasis is an inflammatory skin disease that is commonly associated with flare-
ups after upper respiratory tract infections with β-hemolytic streptococci [301]. Some 
studies observe TCR Vβ-restricted T cell stimulation in the disease [302–304], but others 
have indicated oligoclonal T cell infiltration in psoriasis lesions suggesting a role for a 
more conventional antigen and potential autoimmunity [305]. It is possible that SAg-
mediated activation of T cells could be driving an autoimmune response; however, further 
research on this topic is required. 
Much like the implications for guttate psoriasis, ARF is a known post-streptococcal 
autoimmune sequela that can affect multiple tissues. Cross-reactive immune sera to these 
tissues are thought to be the etiological agent, and SAgs may potentially stimulate 
autoreactive immune cells. There is high correlation between M18 ARF S. pyogenes 
isolates and the speL and speM SAg genes as well as antibodies in ARF patients to these 
SAgs [306,307]. However, it was also shown that antibodies against SAgs did not predict 
susceptibility in Australian Aboriginals [308], indicating that other factors may also play a 
role in ARF development. 
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1.7.10 Other virulence factors 
The above mentioned list of GAS virulence factors is by no means an exhaustive list, but 
does describe some of the best studied factors. S. pyogenes has numerous elements that 
contribute to virulence that are not discussed here. For more information on such factors 
please refer to other reviews that give a much broader view of S. pyogenes virulence 
[2,29,309]. 
 Genetic regulation in S. pyogenes 
The regulation of S. pyogenes gene expression is controlled by 13 known two-component 
regulatory systems (TCSs) and at least 30 stand-alone transcriptional regulators. There is 
extensive interplay between these elements making it an extremely complex system. For 
this reason, we will be focusing primarily on the best-studied virulence-associated systems 
and their impact on gene expression. For a more in-depth analysis, McIver and colleagues 
have provided excellent reviews on this topic [106,310]. 
The best characterized TCS in S. pyogenes is CovRS (formerly CsrRS). Like other TCSs, 
CovRS is composed of a sensor histidine kinase, CovS, that is able to sense external signals 
(such as Mg2+ and host antimicrobial peptides [311,312]) and modify a response regulator, 
CovR, that regulates gene expression of numerous virulence factors. Phosphorylation of 
CovR by CovS results in dimerization and the ability to directly bind DNA at the promoter 
region of targeted genes [313,314]. The CovRS TCS is known to influence up to 15% of 
all GAS chromosomal genes, including the hyaluronic acid capsule, SpeB cysteine 
protease, streptokinase and SLS [164]. CovR is generally a repressor of many virulence 
factors, and mutational analysis of CovRS TCSs demonstrates that a non-functioning 
CovRS switches S. pyogenes to a hypervirulent phenotype in which SpeB gene expression 
is reduced, and numerous virulence factors are upregulated, including SpeA and SLO 
[91,315]. It has been suggested that the transition from localized to systemic infections by 
the globally disseminated M1T1 GAS serotype is due to this CovRS mutation leading to 
the hypervirulent phenotype [316]. The complete role that CovRS plays during human 
infection is not completely understood, and since strains are still able to exist with and 
without a functional CovRS TCS, more research on this topic is warranted. What is known, 
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is that this TCS impacts a large proportion of GAS genes and a broader understanding of 
its influences will aid in our understanding of this complex pathogen.  
‘Stand-alone’ regulators are those that control gene expression in response to outside 
stimulus yet the exact signal and cognate sensory element remain undefined. There are 
three main ‘stand-alone’ regulators in S. pyogenes and they include: Mga (the multiple 
gene regulator of GAS); RALPs (RofA-like proteins); and Rgg/RopB.  
Mga was originally classified as virR (virulence regulator) by one group that found M 
protein negative M12 isolates with a mutation upstream of the emm gene [317]. Another 
group found a comparable locus in a M6 strain of GAS and called it mry (M protein RNA 
yield) [318]. It was eventually determined that these were both actually the same regulator 
and the culminating name was changed to Mga [319,320]. One of the two divergent mga 
alleles (mga-1 and mga-2) can be found in every strain of GAS [321,322] and it is known 
that Mga transcriptionally activates genes during exponential growth of the organism 
[106]. Along with the M protein, Mga also upregulates the virulence factors ScpA and SIC, 
fibronectin-binding and collagen-like proteins as well as carbohydrate utilization and 
metabolism genes [106]. It is important to note that other pathogenic streptococci have 
Mga orthologs [323,324] and there is evidence that Mga plays a role in the early acute 
phase of infection in vivo [325–328]. 
The RALP family includes four proteins found in GAS (RofA [RALP1]; Nra [RALP2]; 
RALP3 and RivR [RALP4]) as well as orthologous members in other pathogenic 
streptococci [106,329]. All analyzed GAS strains have at least RofA or Nra, and potentially 
several other RALP members resulting in RALP-member and RALP-regulation variability 
[322,330]. Genes regulated by RALP include microbial surface components recognizing 
adhesive matrix molecules (MSCRAMMs; such as those for pilus biosynthesis, 
fibronectin-binding proteins), hemolysins (SLS), proteases (SpeB) and SAgs (SpeA) [330–
333]. The RALP family is primarily involved during the transition from exponential to 
stationary growth and impacts host-pathogen interactions and avoidance of host cell 
damage [330,333,334]. 
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The Rgg/RopB transcription regulator family of DNA-binding proteins can be found in 
both GAS [335,336] and closely related organisms [337–341]. This response regulator 
family seems to play a role in modulating virulence at times of nutritional limitation and 
stress. Rgg/RopB plays its largest role in post-exponential growth, but there is high strain 
variability in that it can impact as few as two core genes or as much as >30% of the genome 
[342,343]. Of the genes influenced by Rgg/RopB, there seems to be a repression of mga-
related proteins (SIC, M protein, etc.) as well as SLO and streptokinase, and activation of 
virulence factors such as SpeB, the SAg SpeG, the α2-macroglobulin-binding protein 
[76,343–346] and proteins involved with amino acid catabolism [344,347].  
 Animal models of Group A Streptococcus infection 
No in vitro, in situ or in silica model is able to replicate the extreme complexities that exist 
within a host, and thus in vivo infection models are used in essentially all pathogenesis 
research. The study of S. pyogenes is no different, and in addition to this, a number of 
factors make working with this pathogen more difficult. The first issue is that GAS is a 
human-specific pathogen, and thus a number of its virulence factors have evolved to 
interact with only human immune components. Therefore, regardless of the model used, 
there is likely to be an issue with proper interaction of bacterial and host factors. Second, 
this organism can cause numerous types of infections of varying severity at different 
locations in the host. Consequently, numerous models are required to assess factors 
involved with each of these infections, resulting in further complexities. Lastly, the strain 
to strain variability in this organism is extensive, and thus there is no reference strain that 
best exemplifies all other strains. These difficulties have not stopped researchers from 
trying to understand this organism; on the contrary, there are numerous models from 
invertebrates to non-human primates that have been extremely helpful in revealing the 
complexities of host-pathogen interactions. The focus here will be on one of the best-
studied models, the murine model, as well as the most characteristic of actual human 
infection, the non-human primate model. 
32 
 
1.9.1 Murine models of infection 
Mouse models present an excellent opportunity to study host-pathogen interactions. As 
mammals, they contain both an innate and adaptive immune system that are similar to that 
of humans. In addition, they are relatively inexpensive to purchase and house, quick to 
reproduce, mature rapidly and there are numerous tools available to aid in the study of 
almost any aspect of murine biology. Mice can also be bred to select for desired traits, and 
can be genetically altered to express functional human genes [168,348]. For these reasons, 
they have been extensively used in pathogenesis research. 
Murine streptococcal subcutaneous infections, pioneered by the modern ulcer and air sac 
models [349,350], mimic a broad range of highly inflammatory localized soft tissue 
lesions. Strengths include rapid bacterial proliferation and extensive recruitment of 
inflammatory innate immune cells which imitates what is seen in human infections [349–
351]. However, a major limitation of these models is that histopathology of the infections 
is not the same as that observed in human manifestations due to the thinner murine 
epidermal layer. Also, for S. pyogenes pathogenesis mice may be a good model for the 
innate, but arguably not the adaptive, immune response since a protective immune response 
does not develop after resolution of the infection [352]. Regardless of the limitations, this 
model is considered to be one of the most versatile and useful models for studying S. 
pyogenes pathogenesis. 
Murine models of systemic disease differ in their inoculation route and are generally 
performed by either intravenous (IV), intraperitoneal (IP) or intramuscular (IM) injections. 
These models are heavily used due to their technical simplicity [100,353,354], although 
direct inoculation into the bloodstream, peritoneal cavity or muscle bypass a crucial barrier 
that GAS normally must traverse. It is for this reason that intratracheal (IT) administration 
of bacteria has become more popular. Requirement of the bacteria to traverse the lung 
epithelial more closely resembles human infection whereby sepsis occurs after a localized 
infection in soft tissue [132,355,356]. Researchers have found that IT inoculation is more 
efficient at investigating the role of virulence factors in inducing systemic disease [357–
359]. It is important to note that mouse strain, gender and genetics all play an important 
role in regards to systemic infection and the absence of adaptive immunity also does not 
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impact infectivity [360]. An additional implementation to better mimic human infections 
is the use of transgenic mice expressing human genes. Due to S. pyogenes being a human 
specific pathogen, certain virulence factors are tailored to interact with only human 
immune components and expression of these molecules in a murine system has been shown 
to increase susceptibility of mice to systemic infections [168]. 
As mentioned previously, SAgs are associated with TSS and administration of these toxins 
to mice is used as a model to study TSS. However, SAgs interact poorly with murine 
immune components [361] and sensitizing agents such as D-galactosamine, LPS or 
actinomycin were previously used to help induce this disease [362,363].  It was later found 
that these sensitizing agents induced a viral hepatitis-like liver injury which is not 
characteristic of human TSS (multi-organ dysfunction phenotype, not just a single organ) 
[364–367]. It was shown that mice expressing human leukocyte antigen (HLA) transgenes 
better replicated the human disease, and has thus become the gold-standard [368]. 
Numerous studies have since used this model to further develop our understanding of the 
role of HLA-molecules in both bacterial- and toxin-induced sepsis [264,265,369,370]. It 
has also been shown that different HLA types can render humans either protected or 
susceptible to invasive GAS infections [371], increasing the relevance of this transgenic 
mouse model. 
The most prevalent host-pathogen interactions involving GAS are pharyngitis and 
nasopharyngeal asymptomatic carriage [4,23]. This indicates that the primary reservoir for 
S. pyogenes is the human upper respiratory tract, more specifically, the mucosal-associated 
lymphoid tissue known as Waldeyer’s ring (including the tonsils). It is important to note 
that mice lack this tissue, but instead have a functional homologue known as the nasal-
associated lymphoid tissue (NALT) inside their nostrils [372–374]. This, and the 
surrounding tissue (ethmoid turbinates, maxillary sinus and septum) make up what is 
known as the complete nasal turbinate (cNT) (Figure 2). Murine models of nasopharyngeal 
GAS infection/carriage involve administering a bolus of bacteria into the nares to seed this 
tissue and have been extensively used [110,354,375–377]. Numerous factors can also play 
a role in determining efficiency of infection, including: quantity and volume injected, 
duration of infection, bacterial strain, and mouse strain used. Inoculum volume is generally  
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Figure 2. The murine complete nasal turbine. 
Coronal transverse sections of formalin-fixed mouse head stained with hematoxylin and 
eosin. Indicated architecture is labelled: ethmoid turbinates (ET), maxillary sinus (MS), 
nasal-associated lymphoid tissue (NALT) and the septum. The collective tissue 
environment is referred to as the complete nasal turbinates (cNT). 
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less than 20 µL as volumes greater than this have been shown to seed bacteria into the lung 
and cause pneumonia [376]. Duration of infections vary on amount of bacteria inoculated, 
but mice generally clear infections in 7-14 days, with some potentially harboring bacteria 
for longer [110,376,377]. Bacterial quantitation can be assessed using numerous methods: 
from sacrifice and tissue procurement for end point counts, nasal shedding assay (whereby 
nares are pressed against agar plates for bacterial enumeration) and bioluminescent 
imaging. The murine cNT is also an ideal location for live imaging and genetically 
engineered bioluminescent strains of GAS have been used in this model [375,378]. 
Analysis of the immune system in response to GAS nasopharyngeal infection has 
demonstrated a CD4+ T cell-mediated clearance of bacteria that also involved neutrophils 
[354,379–381]. This demonstrated that both innate and adaptive immune cells can 
contribute to clearance of S. pyogenes in this model. It is important to note that the majority 
of intranasal infection models have used conventional laboratory mice (C57Bl/6, BALB/c, 
FVB, CD1, etc.) [375,376,378,379,382], however, it was recently shown that transgenic 
mice expressing human MHC II (HLA-DQ8) are much more susceptible to infection by S. 
pyogenes and may represent a much more relevant model [377]. However, limitations 
include the relatively short duration of infection/colonization, the differential architecture 
of the cNT from human tonsillar tissue, technical difficulty in isolating cNT tissue and the 
limited number of S. pyogenes strains that have demonstrated the ability to infect this 
tissue. 
The limited duration of GAS nasopharyngeal infection was an issue not easily solved by 
making modifications to the existing model. However, since S. pyogenes is known to 
colonize the female genital tract [383–385], an alternative approach to study this host-
pathogen interaction was adapted from a model previously used with other mucosal 
pathogens (Group B Streptococcus [386], N. gonorrhoeae [387] and Candida albicans 
[388]) using estradiol-primed conventional laboratory mice (C57Bl/6 and BALB/c) [389]. 
Estrous phase mice are vaginally inoculated with GAS and lavages can be taken to count 
bacterial load over several weeks to months. This duration, asymptomatic nature of 
infection, and the non-lethal measurements of bacterial burden (and cytokines) by lavage 
have allowed for the investigation of factors involved in longitudinal mucosal carriage of 
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GAS [389,390]. Limitations include strain variability, the normal microflora must be 
eliminated prior to colonization, and only estrogen-treated female mice can be used [389]. 
1.9.2 Non-human primate models of infection 
Animal infection models that resemble humans, the only known reservoir for GAS, are 
extremely important for understanding host-pathogen interactions and testing of potential 
therapeutics. As close biological relatives, non-human primates are a very attractive 
candidate for this role. The use of baboons (Papio cynocephalus) [391] and cynomolgus 
macaques (Macaca fascicularis) [89,392–394] have been used to study invasive models 
such as sepsis and necrotizing fasciitis. Because of the highly similar anatomy and 
physiology, much can be garnered from these models such as relative body temperature, 
heart rate, blood pressure, serum chemistry, cytokine profiles and post-mortem organ 
analysis.  
Unlike the above mentioned mouse models of colonization, non-human primates present a 
unique opportunity to establish a more human-like infection that develops a better 
representative immune response with easier access to the site of infection, larger blood and 
tissue samples for more analyses and importantly is more receptive to different strains of 
S. pyogenes. For decades, researchers have examined the ability of GAS to infect the 
oropharyngeal tissue of numerous non-human primates including: baboons [395,396], 
rhesus macaque (Macaca mulatta) [397,398], chimpanzees (Pan) [399,400] and 
cynomologus macaque [401], of which the latter is the current most common model. This 
is because baboons and rhesus macaques do not seem to develop symptomatic pharyngitis, 
but chimpanzees and cynomologus macaques do, along with most signs and symptoms 
(erythema, fever, tonsillar enlargement and palatal petechiae) [402,403]. In a short time, 
an immense amount of information about host-pathogen interaction has been discovered 
using these models including a dynamic humoral response during infection, genetic 
regulation, and energy metabolism by GAS during pharyngitis [327,392,403–407]. Despite 
the cost and ethical considerations, the non-human primate model remains the most 
comprehensive tool for studying host-pathogen interactions during S. pyogenes infection 
and colonization. 
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 Group A streptococcal vaccines 
Despite decades of research there is currently no licensed vaccine against S. pyogenes. The 
reasons for this include: concern over vaccines containing autoimmune epitopes, strain 
variability (surface molecule differences, infection site preference and severity, global 
distribution) and the primary effected population. A primary goal for vaccine development 
is the prevention and reduction in major GAS-associated mortality. By far the leading cause 
of death associated with S. pyogenes is autoimmune RHD [4,30,36] and an effective 
vaccine should aim at prevention of this disease. The epitope(s) responsible for the 
autoimmune response in ARF and other autoimmune sequelae have been implicated in the 
M protein, group A carbohydrate and hyaluronic acid capsule, among other GAS factors, 
which has best been reviewed by Madeline Cunningham [408,409] and Jonathan Carapetis 
[30]. It is for these reasons that vaccine candidates must be rigorously studied to ensure 
that they do not contain these epitopes. A major setback occurred in the late 1960s after a 
crude M protein vaccine was tested in children that resulted in ARF cases in the tested 
population [410,411]. This result led to a United States federal ban on GAS vaccine testing 
in humans, which was removed in 2006. The fact that all of the GAS autoimmune epitopes 
remain elusive provides a significant hurdle to vaccine development. Demonstration of M 
protein-type immunity against GAS has been known to be protective for decades [412], 
making this by far the most studied vaccine candidate. The more recent demonstration of 
the growing GAS emm-types (currently over 200) and the difference in their global 
distribution has made the pursuit of this vaccine less logistical for global control of this 
pathogen [14,49,60]. The last major concern is that approximately 95% of the population 
that would benefit most from a GAS vaccine live in low- and middle-income countries [4]. 
This produces a significant financial burden on the project as potential vaccine 
development companies may refrain from pursuing this due to a lack of return on 
investment. All of these hurdles must be overcome to generate a safe, effective and 
affordable GAS vaccine. 
1.10.1 M protein vaccines 
The realization that anti-M protein antibodies produced following natural infection could 
be protective against GAS infection due to promotion of phagocytosis [412,413] spurred 
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the investigation of using these molecules as potential vaccine candidates. Further analyses 
indicated that antibodies against the hypervariable N-terminus were protective and not 
likely to cross-react with host tissue [414]. Eventually, it was realized that protective 
epitopes could be linked together to create long peptides containing many protective 
epitopes against numerous emm-types. This technology led to the development of multi-
valent M protein-based vaccines [414–418], of which two have made it past Phase I and 
Phase II clinical trials and have been shown to be both safe and effective [419,420]. Perhaps 
the greatest hurdle that these vaccines must overcome however, is the high variability 
(>200 emm-types) and wide distribution of the GAS emm-types [49]. Epidemiological data 
[14,58,421,422] suggests that the currently developed 30-valent vaccine [418] would 
protect against isolates responsible for 98% of pharyngitis cases in Canada and the U.S., 
90% of invasive isolates in the U.S., and 78% of invasive isolates in Europe. Interestingly, 
protection against serotypes not in the vaccine were also demonstrated which may lead to 
significant protection in other populations [423,424]. These unexpected findings further 
demonstrate the potential efficacy of a multi-valent N-terminal M protein vaccine. 
Another approach taken to generate M protein vaccines is the use of epitopes found on the 
more conserved, C-terminal region of the protein. Research has demonstrated that the C-
repeat region of the M protein is highly conserved, contains protective epitopes, and thus 
represents a possible vaccine candidate. Original vaccine studies used the entire C-terminal 
region of the M6 protein [425], which future investigation later focused on specific B and 
T cell epitopes [426–428]. One of the best studied C-terminal vaccines is known as J8-DT, 
which is comprised of a stabilized M protein B cell epitope fused to the diphtheria toxoid 
(DT) to enhance immunogenicity [426]. Passive and active immunization has proven 
protective in infection models [426,429,430], long-term B cell memory is induced [431], 
and no host cross-reactive antibodies are generated upon vaccination [432]. Due to its 
success in animal models, J8-DT is currently undergoing Phase I clinical trials [433]. A 
second M protein conserved region vaccine candidate, known as StrepInCor, is a 55 amino 
acid peptide modeled after B and T cells epitopes from the C2 and C3 regions of an M5 
protein [427]. Vaccination with StrepInCor demonstrated mucosal and systemic antibodies 
[428] which were able to opsonize several S. pyogenes strains [434] and protected mice 
from infection with no cross-reactivity to cardiac proteins or other tissues [435,436]. 
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Despite promising in vivo animal efficacy, there have been no human clinical trials as of 
yet. 
1.10.2 Streptococcal superantigen-based vaccines 
The known association of SAgs with TSS led to investigations of whether or not toxoid 
(inactive) molecules could be used in vaccinations to prevent the onset of the disease. 
Vaccination with TCR and/or MHC II binding site mutant SAg toxoids were non-lethal, 
stimulated antibody responses, and were protective in a rabbit model of TSS [437,438]. 
Vaccination of HLA-DQ8 mice with either toxoid SpeA alone or fused to inactive SpeB 
generated antibodies that protected mice from lethal wild-type SpeA challenge, and the 
fusion vaccine also significantly increased survival in a S. pyogenes sepsis model [439]. 
This protective antibody phenotype is supported by the fact that IVIG contains neutralizing 
anti-SAg antibodies and administration of IVIG in humans has been shown to reduce 
mortality in cases of STSS [21,22,440]. However, the efficacy of IVIG therapy for the 
treatment of invasive streptococcal disease remains controversial [441,442]. With new 
understandings of SAgs and their role in both severe/invasive diseases as well as acute 
uncomplicated infections and asymptomatic colonization [245], further study is warranted 
in using toxoid SAgs as potential vaccine candidates.  
1.10.3 Other vaccine candidates 
Although M protein based vaccines are the only candidates that have made it into clinical 
trials, numerous other antigens have undergone pre-clinical, animal model protection 
analysis including: SpeB [439,443]; the GAS carbohydrate [444]; C5a peptidase 
[110,382,445,446], SpyCEP [92], fibronectin-binding protein [447] and others 
[381,433,448]. Analysis of current GAS vaccines would indicate that we are close to 
having strain-specific vaccines available, but still well behind in the development of a 
globally-protective GAS vaccine. Numerous antigens have proven protective in animal 
models of infections and it would seem most likely that a full protective vaccine would 
come from a multi-component vaccine including multiple M protein serotypes and 
numerous other antigens. However, there is a difficulty in acquiring funding to pursue 
Phase I clinical trials for human safety and efficacy of these vaccines. More resources 
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should be allocated towards the development of GAS vaccines, as it would have a major 
impact on prevention of worldwide, GAS-associated morbidity and mortality. 
 Rationale and Hypothesis 
On a global scale, S. pyogenes is a major cause of morbidity as well as mortality, and there 
is currently no licensed vaccine against this organism [4,433]. Recently, our laboratory has 
determined that streptococcal SAgs play not only an important role in severe diseases, but 
also in nasopharyngeal infection establishment [449]. In this model, S. pyogenes 
MGAS8232, an M18 rheumatic fever clinical isolate [306], was efficient at infecting the 
cNT of transgenic mice expressing human MHC II (HLA) but not conventional C57Bl/6 
mice. Using genetic knockout and complementation, this infection was also found to be 
dependent on the SAg SpeA. In the work to be described, we speculate that in the above 
mentioned model, in vivo production of SAgs by S. pyogenes can be detected using flow 
cytometric analysis of the T cell activation marker CD25 on SAg-targeted, but not other, 
T cell subsets in the local immune environment. This SAg-dependent infection phenotype 
also led us to hypothesize that anti-SAg antibodies – provided by either passive 
immunization or active vaccination with an attenuated SpeA toxoid – would be protective 
in a murine model of GAS upper respiratory tract infection. Finally, since it is known that 
Vβ-specific T cell activation is a hallmark of SAg activity, we propose that these T cells 
are required to be present and functional for S. pyogenes nasopharyngeal infection. 
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Chapter 2: Materials and Methods  
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 Materials and Methods 
All solutions and media were made using water purified with a MilliQ filtration system 
(EMD Millipore; Darmstadt, Germany). 
 Ethics statements 
The use of primary human lymphocytes was reviewed and approved by Western 
University’s Research Ethics Board (REB) for Health Sciences Research Involving Human 
Subjects (Appendix 1). Informed written consent was obtained from all donors. All animal 
experiments were completed under Animal Use Protocol (AUP) Number 2011-088 in 
accordance with the Canadian Council on Animal Care Guide to the Care and Use of 
Experimental Animals, and was approved by the Animal Use Subcommittee at Western 
University (London, ON, Canada) (Appendix 2).  
 Bacterial growth conditions 
A complete list of bacterial strains used in this study can be found in Table 3. 
2.2.1 Escherichia coli  
E. coli strains were grown in Luria-Burtani (LB; EMD Millipore) broth, containing 1.5% 
(w/v) agar (Thermo Fisher Scientific Inc.; Waltham, MA, USA) when required, aerobically 
at 37°C. For cultures containing pET28 or pET41 plasmids, cultures were supplemented 
with 50 µg mL-1 kanamycin (Sigma-Aldrich Canada Co.; Oakville, ON, Canada). A 
complete list of plasmids used in this study can be found in Table 4. Frozen stock cultures 
were stored in LB broth plus 25% (v/v) glycerol.  
2.2.2 Streptococcus pyogenes 
S. pyogenes strains were grown statically at 37°C in Todd Hewitt broth (Becton Dickinson 
[BD] Biosciences; Franklin Lakes, NJ, USA) supplemented with 1% (w/v) yeast extract 
(BD Biosciences) (THY). For solid media preparation, 1.5% (w/v) agar (Thermo Fisher 
Scientific) was added to broth. To restore capsule, S. pyogenes MGAS8232 was grown in 
THY broth supplemented with 5% (v/v) human plasma (HP). Human plasma was collected 
from healthy donors and diluted 1:1 in Roswell Park Memorial Institute (RPMI; Life  
44 
 
 
 
 
 
 
Table 3: Bacterial strains used in this study 
Strain Description Source 
Escherichia coli   
XL1 Blue Cloning Strain 
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 
lac [F′proABlaclqZΔM15 Tn10 (Tetr)] 
Stratagene 
BL21 (DE3) Protein Expression Strain  
F- ompT hsdSB(rB
-, mB
-) gal dcm (DE3) 
Novagen 
Streptococcus pyogenes   
MGAS8232 M18 strain isolated from patient with acute 
rheumatic fever 
[306] 
SF370 M1 strain isolated from wound of infected 
patient 
[450] 
Streptococcus pneumoniae   
P1121 Serotype 23F derived from nasopharyngeal 
human carriage of strain P833 
Dawn 
Bowdish 
[451–453] 
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Table 4: Plasmids used in this study 
Plasmid Descriptiona Source 
pET-28a(+) Protein expression vector; N-
terminal His•Tag®/thrombin cut site; 
Kanr  
Novagen 
pET-28a(+)::TEV pET-28a(+) plasmid with modified 
TEV protease cleavage site; Kanr  
McCormick Lab 
pET-41a(+) Protein expression vector; N-
terminal GST•Tag/His•Tag®; Kanr 
Novagen 
pET-41a(+)::TEV pET-41a(+) plasmid with modified 
TEV protease cleavage site; Kanr  
[228] 
pET-28a(+)::TEV:: 
speA 
speA inserted into NcoI and BamHI 
of pET-28a::TEV; Kanr 
[377] 
pET-28a(+)::TEV:: 
speAN20A 
Asn to Ala at mutation position 20 
in speA; Kanr 
This Study 
pET-28a(+)::TEV:: 
speAL41/42A 
Leu to Ala mutation at positions 41 
and 42 in speA; Kanr 
This study 
pET-28a(+)::TEV:: 
speAY100A 
Tyr to Ala mutation at position 100 
in speA; Kanr 
[377,454] 
pET-28a(+)::TEV:: 
speAN20A/Y100A 
Asn (at position 20) and Tyr (at 
position 100) to Ala mutations in 
speA; Kanr 
This Study 
pET-28a(+)::TEV:: 
speATRI 
Leu (at positions 41 and 42) and Tyr 
(at position 100) to Ala mutations in 
speA; Kanr 
This Study 
pET-28a(+)::TEV:: 
speATETRA 
Asn (at position 20), Leu (positions 
41 and 42) and Tyr (at position 100) 
to Ala mutations in speA; Kanr 
This Study 
pET-28a(+):: 
speAHEXA 
Gln to His at position 19, Asn to 
Asp at position 20, Leu to Ala at 
positions 41 and 42, Asp to Asn at 
position 45 and Cys to Ser at 
position 98 mutations in speA; Kanr 
[437] 
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pET-28a(+)::TEV 
speAHEXA 
speA mutant from Roggiani et al. 
[437] inserted into NcoI and BamHI 
of pET-28a::TEV; Kanr 
This Study 
pET-41a(+)::TEV:: 
speC 
speC gene inserted into NcoI and 
BamHI of pET-41a::TEV; Kanr 
[208] 
pET-28a(+)::TEV:: 
speG 
speG inserted into NcoI and BamHI 
of pET-28a::TEV; Kanr 
[377] 
pET-28a(+)::TEV:: 
speH 
speH inserted into NcoI and BamHI 
of pET-28a::TEV; Kanr 
McCormick Lab 
pET-28a(+)::TEV:: 
speI 
speI inserted into NcoI and BamHI 
of pET-28a::TEV; Kanr 
[206] 
pET-28a(+)::TEV:: 
speJ 
speJ inserted into NcoI and BamHI 
of pET-28a::TEV; Kanr 
McCormick Lab 
pET-28a(+)::TEV:: 
speK 
speK inserted into NcoI and BamHI 
of pET-28a::TEV; Kanr 
McCormick Lab 
pET-28a(+):: 
speL 
speL inserted into NcoI and BamHI 
of pET-28a; Kanr 
[377] 
pET-28a(+):: 
speM 
speM inserted into NcoI and BamHI 
of pET-28a; Kanr 
[377] 
pET-28a(+):: 
ssa 
ssa inserted into NcoI and BamHI of 
pET-28a; Kanr 
McCormick Lab 
pET-41a(+)::TEV:: 
smeZ 
smeZ gene inserted into NcoI and 
BamHI of pET-41a::TEV; Kanr 
[377] 
pET-28a(+)::TEV:: 
seb 
seb inserted into NcoI and BamHI of 
pET-28a::TEV; Kanr 
[455] 
a Abbreviations: Kanr, kanamycin resistance; TEV, tobacco etch virus protease 
cleavage site 
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Technologies Inc.; Carlsbad, CA, USA) 1640 media. THY media with 5% (v/v) HP was 
sterilized by 0.2 µM filtration (Pall Life Sciences; Port Washington, NY, USA). Frozen 
stock cultures were created by addition of 20% (v/v) glycerol to THY media. 
2.2.3 Streptococcus pneumoniae 
S. pneumoniae was grown in Tryptic Soy broth (TSB; BD Biosciences) statically at 37°C 
in 5% CO2. Frozen stocks were prepared by addition of 20% (v/v) glycerol into TSB media. 
 Growth curves 
S. pyogenes and S. pneumoniae strains were grown from -80°C freezer stocks and 
subcultured twice (1%) in their respective medias (THY and TSB) at the appropriate 
conditions stated above. Overnight culture optical densities at 600 nm (OD600) were 
corrected to a value of ~0.05 in 100 mL of media. Bacteria were grown in appropriate 
conditions and OD600 readings were measured every hour using a spectrophotometer (DU
® 
530 Life Sciences UV/Vis Spectrophotometer; Beckman Coulter Canada LP; Mississauga, 
ON, Canada). Once a logarithmic growth phase was determined, the growth curve was 
repeated with serial dilution and spot plating during this phase. Bacterial counts were used 
to generate a linear relationship between OD600 and bacterial concentration, with a line of 
best fit and equation of the slope for bacterial preparation for infection. 
 Deoxyribonucleic acid 
2.4.1 Plasmid isolation from E. coli 
Plasmid DNA was isolated from 5 mL of pelleted E. coli after growth to stationary phase 
(O/N aerobic growth at 37°C). Pelleted bacteria were treated using QIAprep spin miniprep 
kit (Qiagen; Hilden, Germany) or E. Z. N. A. kit (Omega Bio-Tek; Norcross, GA, USA) 
as per manufacturer’s instructions. Plasmid DNA was eluted in sterile water. A complete 
list of plasmids can be found in Table 4. 
2.4.2 Genomic DNA isolation from murine tissue 
Genomic DNA was prepared according to The Jackson Laboratory (Bar Harbor, ME, 
USA). Briefly, mouse ears were notched for identification purposes prior to being weaned 
(approximately two weeks after birth). Removed tissue was stored at -20°C until use. 
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Tissue was added to 75 µL of 25 mM NaOH, 0.2 mM EDTA and placed in a thermocycler 
at 98°C for 1 hour followed by a reduction to 15°C until proceeding to the next step. An 
addition of 75 µL of 40 mM Tris HCl (pH 5.5) was then made prior to centrifugation at 
4,000 × g for 3 minutes. The supernatant was then used as template for polymerase chain 
reaction. 
2.4.3 Polymerase chain reaction 
All primers used in this study were generated by Sigma-Aldrich and are listed in Table 5. 
Primers were resuspended to a final concentration of 100 µM in MilliQ water. Reactions 
were comprised of 1 × high fidelity buffer (Thermo Fisher Scientific), 2 mM magnesium 
chloride (MgCl2; Thermo Fisher Scientific), 3 mM deoxyribonucleotide triphosphate 
(dNTP) mixture (Roche Diagnostics; Risch-Rotkreuz, Switzerland), 10 pM each of 
forward and reverse primer, at least 1 pg of low complexity (plasmid) or 50 ng of high 
complexity (genomic) DNA and 0.02 units mL-1 of Phusion High-Fidelity DNA 
polymerase (Thermo Fisher Scientific). All reactions were completed on a Peltier 
Thermocycler PTC-200 (MJ Research, Waterdown, MA, USA). Reactions were visualized 
(see below) and products were purified using a QIAquick PCR Purification kit (Qiagen) 
according to the manufacturer’s instructions and eluted in sterile MilliQ water. 
 Plasmid mutagenesis and gene amplification 
Cycling for megaprimer plasmid mutagenesis and general gene amplification was as 
follows: 98°C for 5 minutes as an initial denaturing step; 98°C for 30 seconds, 0.5°C per 
second ramp to 53°C annealing, 53°C for 30 seconds, 0.5°C per second ramp to 72°C for 
amplification, 72°C for 4 minutes and 0.5°C ramp to 98°C, repeat for a total of 32 cycles. 
The final extension step was 72°C for 5 minutes and reactions were set to 4°C before 
removal from thermocycler. 
 Mouse genotyping 
Cycling for mouse genotypes were as follows: Initial denaturing step at 98°C for 4 minutes 
and 30 seconds. Cycle begins with 98°C denaturing for 20 seconds, annealing at 50°C for 
45 seconds, amplification at 72°C for 15 seconds; repeat cycle 29 times. Final extension  
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Table 5: Primers used in this study 
Primer Sequence (5′ – 3′)a Purpose 
T7 promoter TAA TAC GAC TCA CTA TAG GG Sequencing 
T7 reverse CGC CAG GGT TTT CCC AGT CAC GAC Sequencing 
NcoI His TEV speA 
For 
CCC CCA TGG GCA GCA GCC ATC ATC 
ATC ATC ATC ACA GCA GCG GCG AAA 
ACT TGT ATT TCC AAG GCC AAC AAG 
ACC CCG ATC CAA GCC A  
Gene 
amplification 
BamHI speA Rev CCC GGA TCC TTA CTT GGT TGT TAG 
GTA GAC TTC AAT  
Gene 
amplification 
speA N20A For AAA AAC CTT CAA GCA ATA TAT TTT 
CTT 
Mutagenesis 
speA N20A Rev AAG AAA ATA TAT TGC TTG AAG GTT 
TTT 
Mutagenesis 
speA L41/42A For TCT GTT GAT CAA GCA GCA TCT CAC 
GAT TTA 
Mutagenesis 
speA L41/42A Rev TAA ATC GTG AGA TGC TGC TTG ATC 
AAC AGA 
Mutagenesis 
DQA (1027) For GAA GAC ATT GTG GCT GAC CAT GTT 
GCC 
Mouse 
genotype 
DQA (1029) Rev AGC ACA GCG ATG TTT GTC AGT GCA    
AAT TGC GG 
Mouse 
genotype 
DQ8b (vA) For AGG ATT TGG TGT ACC AGT TTA AGG    
GCA T 
Mouse 
genotype 
DQ8b (vii) Rev TGC AAG GTC GTG CGG AGC TCC AA Mouse 
genotype 
DR4A (1101) For GGA GAT AGT GGA ACT TGC GG Mouse 
genotype 
DR4A (1104) Rev CCG ATC ACC AAT GTA CCT CC Mouse 
genotype 
DR4B (1098) For GTT TCT TGG AGC AGG TTA AAC A Mouse 
genotype 
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DR4B (1099) Rev CTG CAC TGT GAA GCT CTC AC Mouse 
genotype 
a Underlined nucleotides represent restriction enzyme recognition sites; bolded 
nucleotides represented mutated amino acids 
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was completed at 72°C for 4 minutes, and reactions were set to 4°C until removed from 
thermocycler. 
2.4.4 Visualization 
UltraPure™ Agarose (Invitrogen, Life Technologies Inc.) at 1% or 2% (w/v) in 40 mM Tris-
acetate, 1mM EDTA (TAE) buffer was used to visualize DNA. Samples were mixed 5:1 
with DNA loading dye (40% [v/v] glycerol, 0.25% [w/v] bromophenol blue [International 
Biotechnologies; New Haven, CT, USA]) prior to gel loading. Electrophoresis was 
performed for 1 hour at 100 V (Bio-Rad Laboratories Inc.; Hercules, CA, USA). A standard 
DNA molecular weight ladder (1 Kb; Invitrogen) was included in each gel as a size marker. 
Agarose gels were stained with 0.05% (v/v) ethidium bromide (EMD) in TAE buffer for 
approximately 20 minutes and visualized using ultraviolet light (Gel Doc™, Bio-Rad 
Laboratories Inc.). 
2.4.5 Gel extraction 
DNA was visualized as stated above and excised from agarose gel under ultraviolet light 
using a scalpel. Extracted DNA was purified using QIAquick Gel Extraction Kit (Qiagen) 
according to the manufacturer’s protocol. DNA was eluted using sterile MilliQ water.  
2.4.6 Quantification 
DNA was quantified using a NanoDrop 1000 Spectrophotometer (Thermo Fisher Scientific 
Inc.).  
 Molecular cloning 
2.5.1 Restriction enzyme digestion 
Restriction enzyme digestions of DNA were completed as per the manufacturer’s 
instructions (New England BioLabs Inc.; Ipswich, MA, USA or Roche Diagnostics). 
Briefly, target DNA with 1 U enzyme µg-1 DNA in enzyme-specific buffer and 1 × bovine 
serum albumin (New England BioLabs Inc.) were incubated for 2.5 hours at 37°C. 
Reactions were visualized (see above) compared to uncut controls, and purified using 
QIAquick PCR Purification kit (Qiagen) as per manufacturer’s instructions and eluted with 
sterile MilliQ water. 
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2.5.2 DNA ligation 
Appropriate concentrations (100 ng:1 ng, vector:insert; 1:1 molar ratio) of purified, 
restriction enzyme digested DNA products were mixed with 1 × T4 Ligase Buffer and 40 
U T4 DNA Ligase (New England BioLabs Inc.) and incubated at 16°C for 1 hour. Ligation 
reactions were directly transformed into rubidium chloride competent E. coli (see below). 
2.5.3 Preparation of rubidium chloride competent E. coli  
Appropriate E. coli culture grown in LB media aerobically overnight at 37°C (stationary 
phase) were subcultured 1:100 into 100 mL PSI broth (5 g/L Bacto yeast extract [BD 
Biosciences], 20 g/L Bacto Tryptone [BD Biosciences], 5 g/L magnesium sulphate, pH 
7.6) and grown to OD600 0.48. Cultures were incubated on ice for 15 minutes followed by 
centrifugation at 4°C for 5 minutes at 5,000 × g. The cell pellet was resuspended in 40 mL 
TfbI buffer (30 mM potassium acetate, 100 mM rubidium chloride, 10 mM calcium 
chloride, 50 mM manganese chloride, 15% [v/v] glycerol, pH 5.8) and incubated on ice for 
15 minutes. Cells were centrifuged again as mentioned above. The pellet was then 
resuspended in 4 mL TfbII buffer (75 mM calcium chloride, 10 mM 3-(N-morpholino) 
propanesulfonic acid [MOPS], 10 mM rubidium chloride, 15% [v/v] glycerol, pH 6.5) and 
aliquots were store at -80°C until use. 
2.5.4 Transformation of competent cells 
Ligation reactions (see above) were transformed into rubidium chloride competent E. coli 
using a heat-shock method. Competent cells were thawed on ice, ligation reaction (~10 µL) 
was added and cells were incubated for 30 minutes on ice. Cells were then placed in a 42°C 
water bath for 45 seconds and subsequently placed on ice for 2 minutes. Cells then had 0.9 
mL LB broth added and were incubated aerobically for 1 hour at 37°C. Transformed 
cultures were then spread plated (200 µL) on LB agar with appropriate antibiotics 
(according to transformed plasmid; see Table 2) and grown overnight at 37°C. 
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 Sequencing of DNA 
Sequencing was completed by the Sequencing Facility at the John P. Robarts Research 
Institute at Western University in London, Ontario, Canada. Sequencing was completed 
with either provided or designated primers (Table 3).   
 Protein production 
2.7.1 Bacterial protein expression 
E. coli BL21 (DE3) containing the appropriate pET expression construct (Figure 3A) was 
inoculated from freezer stock into LB broth containing appropriate antibiotic (Table 2). 
The culture was then grown aerobically overnight at 37°C. Overnight culture was 
subcultured 1:100 into 1L LB broth containing appropriate antibiotic and grown for 3 hours 
aerobically at 37°C. The bacterial culture was then induced with 200 µM isopropyl β-D-1-
thiogalactopyranoside (IPTG) and grown aerobically overnight at room temperature 
(~25°C). The overnight culture was pelleted at 3,500 × g for 10 minutes and resuspended 
in 10 mL of 20 mM Tris base, 200 mM sodium chloride pH 7.5 buffer containing 10 µL 
DNaseI (Sigma-Aldrich) and 50 µL of 10 mg mL-1 lysozyme (Thermo Fisher Scientific 
Inc.) and incubated on ice for 1 hour with shaking. The bacteria was then sonicated for 3 
rounds with 50 pulses each, 40% duty cycle and output 4 on a Branson Sonifier (Emerson 
Industrial Automation; Eden Prairie, MN, USA) with icing between each round. Sonicated 
product was then centrifuged at 10,000 × g at 4°C for 10 minutes and the supernatant was 
collected for gravity nickel column purification. 
2.7.2 Metal affinity column chromatography protein purification 
Supernatants from bacterial lysates were added to a charged (100 mM nickel sulphate) Ni-
NTA affinity column (Novagen, EMD Millipore) and washed with 20 mM Tris base, 200 
mM sodium chloride pH 7.5 buffer containing increasing concentrations of imidazole (5 
mL each; 30 mM, 60 mM and 200 mM Imidazole). Fractions were analyzed by sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE; see below) (Figure 3B) 
and fractions found to contain an abundance of the protein of interest were pooled and 
dialyzed in 1 L of 20 mM Tris base, 200 mM sodium chloride pH 7.5 three times for 1 hour 
per litre. The N-terminal His6 tags were removed from the proteins by addition of either 
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Figure 3. Superantigen plasmid constructs and protein purification. 
A. All wild-type and toxoid SAg genes were cloned in either pET28a or pET41a expression 
plasmids with the indicated purification and cleavage tags. B – D. Protein expression was 
induced using IPTG from E. coli BL21 (DE3) and SAgs were purified from cell lysate 
using nickel-affinity column chromatography. B. Cell lysates were applied to a NiSO4-
charged column and fractions were eluted using increasing concentrations of imidazole. 
SAg-containing fractions were pooled, dialysed to remove imidazole and incubated with 
the appropriate cleaving enzyme. C. The sample was again passed through a charged nickel 
column to remove cleaved His6 tags and His6-tagged TEV. D. Fractions of purified, cleaved 
SAg were collected and dialyzed into appropriate buffer and diluted to the required 
concentration. All visualization was done using 12% v/v SDS-PAGE. FT, flowthrough; W, 
wash; P, purified SAg protein. Column labels indicate concentration of imidazole in the 
wash buffers. 
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 autoinactivation-resistant His7-TEV [456] or thrombin for 24 hours at room temperature. 
The protein solution was then reapplied to a charged Ni-NTA affinity column (Novagen, 
EMD Millipore) to remove His7-TEV and obtain a purified protein sample (Figure 3C). 
Pure protein was then dialyzed three times against 1 L of 150 mM sodium chloride, pH 7.4 
for one hour per litre. Homogeneity was assessed by SDS-PAGE (see below) (Figure 3D). 
2.7.3 Protein quantitation 
Concentration of purified protein was determined using Pierce™ BCA Protein Assay kit 
(Thermo Fisher Scientific Inc.) according to manufacturer’s instructions. Briefly, the 
protein of interest was mixed with working reagent, bicinchoninic acid (BCA), for 
colourimetric detection of protein at an optical density of 562 nm. The protein of interest 
concentration was then determined by comparing with various concentrations of a 
reference protein, BSA. Optical density was read using a Synergy™ H4 Hybrid Multi-Mode 
Microplate Reader (BioTek, Fisher Scientific Inc.). 
 Protein visualization 
2.8.1 Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
Protein samples were mixed 3:1 with 4 × Laemmeli buffer (240 mM Tris-HCl pH 6.8, 8% 
[w/v] sodium dodecyl sulphate [SDS], 40% [v/v] glycerol, 0.01% [w/v] bromophenol blue, 
1% [v/v] β-mercaptoethanol) and boiled for 5 minutes. Samples were then loaded into 15% 
polyacrylamide resolving gels (15% [v/v] acrylamide/bisacrylamide [37.5:1] aqueous 
solution, 0.25% [v/v] 1.5 M Tris-HCl pH 8.8, 0.1% [w/v] SDS, 0.1 % [w/v] ammonium 
persulfate [APS], 0.15% [v/v] tetramethylethylenediamine [TEMED]) with 5% 
polyacrylamide stacking gel (5 % [v/v] acrylamide/bisacrylamide [37.5:1] aqueous 
solution, 25% [v/v] 0.5 M Tris-HCl pH 6.8, 1.3% [w/v] SDS, 0.1 % [w/v] APS, 0.2% [v/v] 
TEMED) and run for 50 minutes at 200 V (Mini-PROTEAN System, Bio-Rad Laboratories 
Inc.) using Tris-Glycine electrophoresis buffer (192 mM glycine, 25 mM Tris, 0.1% [w/v] 
SDS, pH 8.3). Polyacrylamide gels were stained for 1 hour with staining solution (45% 
[v/v] methanol, 10% [v/v] glacial acetic acid, 0.1% [w/v] Coomassie Brilliant Blue R-250 
[Bio-Rad Laboratories Inc.) and immediately placed in destain solution (45% [v/v] 
methanol, 10% [v/v] glacial acetic acid) several times until background staining was 
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resolved. To estimatre protein molecular weight, samples were compared to Prestained 
Broad Range P7708S Protein Marker (New England BioLabs Inc.) or BLUeye Protein 
Ladder (GeneDireX Inc., Taiwan). 
2.8.2 Western blot 
To probe for specific proteins, contents from SDS-PAGE gel (prior to staining procedure) 
were transferred onto polyvinylidine difluoride (PVDF) membrane (EMD Millipore). To 
accomplish this, PVDF membrane was first incubated in 100% methanol for 5 minutes, 
followed by immersion in Western blot transfer buffer (20% [v/v] methanol, 48 mM Tris 
base, 39 mM glycine, 0.037% [w/v] SDS) for 5 minutes. The prepared PVDF membrane 
and SDS-PAGE gel were then assembled together in a Mini Trans-Blot® Cell (Bio-Rad 
Laboratories Inc.) with Western blot transfer buffer and electroblotted for 1 hour at 100 V 
or overnight at 25 V with a cold block. The PVDF membrane was then blocked for 30 
minutes with 5% (w/v) skim milk powder in Tris buffered saline (TBS; 100 mM Tris, 1.5 
M sodium chloride, pH 7.5). Post-blocking, the membrane was incubated for 1 hour with 
primary antibody (polyclonal rabbit anti-SAg; ProSci; see below; Table 6) diluted 
1:10,000 in 1% (w/v) skim milk in TBS. To remove residual antibody, PVDF membrane 
was washed three times in TBS with 0.01% (v/v) tween-20 (TBS-T) for 5 minutes per 
wash. IRDye800-conjugated goat anti-rabbit (Rockland Inc.; Limerick, PA, USA) 
secondary antibody was diluted 1:10,000 in 1% (w/v) skim milk powder in TBS and 
incubated with the PVDF membrane for 1 hour, shielded from light at room temperature. 
The membrane was washed three times with TBS-T as mentioned previously, and imaged 
on a LI-COR® Odyssey Imaging System (LI-COR Biosciences; Lincoln, NE, USA). 
 Antibody generation 
Purified SAg toxins in 150 mM sodium chloride (pH 7.5), were sent to ProSci Inc. (Poway, 
CA, USA) for production of polyclonal rabbit anti-SAg antibodies. New Zealand White 
rabbits were injected with 200 µg of SAg with complete Freund’s adjuvant at week 0, and 
boosted with 100 µg SAg with incomplete Freund’s adjuvant at weeks 2, 4 and 6. Serum 
was collected at week 0, 5 and 7 with terminal bleed taken at week 8. Serum samples were  
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Table 6: Antibodies and dyes used in this study 
Target Fluorophore/Conjugate Clone Source 
Passive Immunization/Western Blot 
SpeA N/A Polyclonal (Rabbit)  ProSci 
SpeC N/A Polyclonal (Rabbit)  ProSci 
Anti-Rabbit IgG IRDye800 Polyclonal (Donkey) Rockland 
T cell Depletion 
CD4  N/A GK1.5 BioXCell 
CD8  N/A YTS169.4 BioXCell 
KLH N/A LTF-2 BioXCell 
Vβ4 N/A KT4 BioXCell 
Vβ8 N/A F23.1 BioXCell 
Flow Cytometry – Mouse 
CD3ε APC 145-2C11 eBioscience 
CD4 APC-eFluor 780 GK1.5 eBioscience 
CD8a PE 53-6.7 eBioscience 
CD25 PE 7D4 BD Pharmingen 
TCR Vβ3 FITC KJ25 BD Pharmingen 
TCR Vβ4 FITC KT4 BD Pharmingen 
TCR Vβ8.1/8.2 FITC KJ16 eBioscience 
Flow Cytometry – Human 
7-AAD N/A N/A eBioscience 
CD3 APC UCHT1 BD Pharmingen 
CD4 BV 711 RPA-T4 BioLegend 
CD8 Alexa Fluor 700 RPA-T8 BD Pharmingen 
CD25 PE M-A251 BD Pharmingen 
PD-1 BV 421 EH12.2H7 BioLegend 
ELISA – Antibody Titre 
Anti-Mouse IgG HRP Polyclonal (Goat) Sigma-Aldrich 
Anti-Mouse IgM HRP Polyclonal (Goat) Rockland 
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assessed for anti-SAg antibody titre using enzyme-linked immunosorbent assay (ELISA; 
see below), aliquoted and stored at -80°C until use. 
 In vivo experiments 
2.10.1 Mice 
Other than size, there were no gender differences (bacterial load, response to SAgs, etc.) 
between male and female mice between any of the strains used in this study. It was 
therefore determined that when possible equal numbers of male and female mice would be 
used in each group, however, this was not a requirement for experimentation. 
 Housing and breeding 
Mice were bred and housed in the West Valley Barrier Facility (Western University, 
London, ON, Canada) and moved to the Animal Holding Facility on the sixth floor of the 
Dental Sciences Building (Western University, London, ON, Canada) for undertaking of 
experiments. In both facilities mice were housed under specific pathogen-free conditions 
with food and water ad libitum. 
 Strains utilized 
A list of all mice used in this study can be found in Table 7. C57Bl/6 mice expressing the 
transgenic major histocompatibility complex (MHC) class II human leukocyte antigen 
(HLA)-DR4 and DQ8 were obtained from the Kotb Laboratory and have been previously 
described [348,369,457]. Mice expressing the DQ8 gene alone were outbred from HLA-
DR4/DQ8 by selecting for mice containing only the HLA-DQ8 allele. Conventional 
C57Bl/6 mice were obtained from The Jackson Laboratory. 
2.10.2 Passive immunization 
HLA-DQ8 mice 12-14 weeks of age were injected in the intraperitoneal cavity with 500 
µL of rabbit anti-SAg serum -24 and -2 hours prior to nasopharyngeal infection with S. 
pyogenes (see below). 
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Table 7. Mouse strains used in this study 
Strain Characteristic Source 
C57Bl/6 Inbred black mouse Jackson Laboratories (Bar 
Harbor, ME, USA) 
HLA-DR4/DQ8 C57Bl/6 mice null for 
endogenous H2b MHC 
class II and transgenic for 
human HLA-DR4 and 
HLA-DQ8 
[369]; McCormick lab 
breeding colony 
HLA-DQ8 C57Bl/6 mice null for 
endogenous H2b MHC 
class II and transgenic for 
human HLA-DQ8 
McCormick lab breeding 
colony 
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2.10.3 Vaccination experiments 
Vaccination of 6-8 week old HLA-DR4/DQ8 mice has been previously described [377]. 
Briefly, mice received 1 µg (unless otherwise stated) SAg or toxoid in 200 µL (100 µL 150 
mM sodium chloride, pH 7.5; 100 µL Imject™ Alum Adjuvant [Thermo Fisher Scientific]) 
subcutaneously under isoflurane anesthetic. Control mice received only saline solution and 
adjuvant. Injections were received on day 0, 14 and 28, and mice were bled via saphenous 
vein on day 42 to assess antibody titre (see below). Mice were weighed on day 0 prior to 
injection, day 7, 21 and 42 to determine if SAg injection had any effect on weight gain. To 
assess T cell responsiveness post-vaccination, spleens were removed on day 43 and 
subjected to an activation assay (see below). Where applicable, nasopharyngeal infection 
occurred on day 43 (see below). 
2.10.4 T cell depletion 
Murine depletion of T cells has been previously described [458]. In brief, HLA-DQ8 mice 
received 300 µg of anti-CD4 (GK1.5; BioXCell; West Lebanon, NH, USA), anti-CD8 
(YTS169.4; BioXCell) or isotype control (LTF-2; BioXCell) alone or in combination in 
500 µL of PBS, pH 7.5. Injections were received on day -7, -6 and -1. On day 0, mice were 
either sacrificed for lymph node procurement and flow cytometric analysis or streptococcal 
infection (see below). 
2.10.5 Murine nasopharyngeal infection  
Mice were given 2 mg ml-1 neomycin sulphate ad libitum in their drinking water two days 
prior to infection to reduce the nasal microbiota. Regardless of infecting bacteria, mice 
were sacrificed 48 hours post infection and cNT, blood, spleen, liver, kidneys, lungs and 
heart were removed for bacterial enumeration and cytokine analysis where indicated. 
 S. pyogenes preparation and inoculation 
Preparation of S. pyogenes MGAS8232 for inoculation has been previously described 
[377,459]. In brief, S. pyogenes MGAS8232 was grown from freezer stock (see above) in 
THY broth statically at 37°C and subcultured 1:100 for two days. On the third day, the 
bacteria was subcultured (7%) into 100 mL of pre-warmed THY broth and grown until an 
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OD600 of ~0.3. Using the equation generated from the bacterial growth curve (see above), 
the appropriate volume containing 1 × 109 CFU was centrifuged at 2,000 × g for 7 minutes 
and the supernatant was removed. The bacterial pellet was transferred to a new container 
and spun at 21,000 × g for one minute. The residual supernatant was removed and the pellet 
was resuspended in 1 mL Hanks’ Balanced Saline Solution (HBSS; Wisent Bioproducts 
Inc.; Saint-Bruno, QU, Canada) and spun as above. The supernatant was again removed 
and the pellet was reconstituted in 150 µL HBSS for murine inoculation. One dose was 
serially diluted and plated to determine the concentration of bacterial inoculum. Mice from 
one of the above mentioned experimental methodologies were then anesthetized using Pr 
FORANE (isoflurane, USP; Baxter Corporation; Mississauga, ON, Canada) and 7.5 µL of 
bacterial inoculum was administered to each nostril. The mice were then allowed to recover 
from the anesthetic and monitored for the duration of the experiment. Inoculation with S. 
pyogenes SF370 was completed as above with the following modification: after being 
grown from the freezer stock, the bacteria were directly subcultured (7% v/v) into 100 mL 
pre-warmed THY media without two days of subculturing. 
 S. pneumoniae preparation and inoculation 
Nasal inoculation of S. pneumoniae was prepared similarly to Puchta el al. [460]. Briefly, 
S. pneumoniae was grown from freezer stock in 10 mL TSB at 37°C with 5% CO2 
overnight. The overnight growth was subcultured (7%) in 100 mL TSB and grown as above 
until an OD600 ~0.3 was reached. Using the generated equation (see above), the appropriate 
volume containing 1 × 108 CFU was spun at 15,000 × g for 1 minute. The supernatant was 
removed and the pellet was resuspended in 100 µL of PBS, pH 7.5. One dose was serially 
diluted and plated to determine the concentration of bacterial inoculum. T cell depleted or 
isotype control treated mice were then anesthetized using Pr FORANE (isoflurane, USP; 
Baxter Corporation; Mississauga, ON, Canada) and 5 µL of bacterial inoculum was 
administered to each nostril. The mice were then allowed to recover from the anesthetic 
and monitored for the duration of the experiment. 
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 Antibody titre analysis 
Antibody titres were determined using ELISA. Wells of a Corning Costar 9018 (Corning; 
Corning, NY, USA) 96-well high-bind plate were coated with 100 µL of indicated SAg 
(10 µg mL-1) in coating carbonate buffer (affymetrix eBioscience; Thermo Fischer 
Scientific) and was left at room temperature overnight in a humidified chamber. Plates 
were subsequently washed twice with distilled water.  Plates were then blocked with PBS 
containing 1% (w/v) bovine serum albumin (BSA) and 0.05% (v/v) tween-20 for 2 hours 
at room temperature and washed as above. Mouse serum samples were diluted starting at 
1:100 in PBS containing 0.1% (w/v) BSA and 0.05% (v/v) tween-20 to a final volume of 
100 µL per well followed by two-fold serial dilutions down the plate until a final dilution 
of 1:204,800 was reached. Plates were incubated at room temperature for 2 hours and 
washed three time in wash buffer (PBS containing 0.05% v/v tween-20) followed by three 
washes with distilled water. Goat anti-mouse horseradish peroxidase (HRP)-conjugated 
secondary antibody (Sigma-Aldrich) was added at a dilution of 1:10,000 to a final volume 
of 100 µL/well and incubated at room temperature for 2 hours.  Plates were washed 5 times 
as above and developed by adding 100 µL/well of 3, 3′, 5, 5′ Tetramethybenzidine (TMB; 
BD Biosciences) for 15 minutes. Colour change was halted by addition of 50 µL of 1 M 
H2SO4 and plates were read at OD450 with OD570 subtraction.  Positive antibody titre was 
calculated as the reciprocal of the lowest serum dilution with readings four-fold above 
background. 
 Ex vivo experiments 
2.12.1 Cell preparation 
 Murine splenocytes 
Spleens were procured from euthanized mice and immediately stored on ice in 5 mL of 
HBSS. Spleens were pressed through a sterile 0.2 µm nylon mesh filter and the single-cell 
suspension was centrifuged at 450 × g for 5 minutes. The supernatant was removed and the 
pellet was loosened via racking. Red blood cells were lysed by addition of 1 mL ammonium 
chloride potassium (ACK) lysing buffer (Thermofisher Scientific Inc.) for 30 seconds. To 
stop the lysis reaction, 10 mL of PBS, pH 7.5 was added and the cells were spun as above. 
Cells were resuspended in 7 mL PBS buffer and sieved through nylon mesh filter as above 
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to remove cell debris. The filter was washed with an additional 7 mL PBS to ensure 
collection of all living cells. The collected sample was spun as above, the supernatant was 
discarded, and the pellet was racked, and then resuspended in 4 mL of complete RPMI 
(cRPMI) media (RPMI-1640 [Life Technologies Inc.] supplemented with 0.1 mM minimal 
essential medium non-essential amino acids [Life Technologies Inc.], 10% [v/v] heat-
inactivated fetal bovine serum [Sigma-Aldrich], 100 units mL-1 penicillin [Life 
Technologies Inc.], 100 µg mL-1 streptomycin [Life Technologies Inc.], 1 mM sodium 
pyruvate [Life Technologies Inc.], and 2 mM L-glutamine [Life Technologies Inc.]). Live 
cells were counted using Trypan Blue (Life Technologies Inc.) exclusion and resuspended 
to a concentration as required for the indicated assay. 
 Murine lymph nodes 
Cervical lymph nodes were procured from anaesthetized mice and immediately 
homogenized in 5 mL of ice-cold PBS, pH 7.5 using a glass homogenizer. Cells were 
processed as above, however, no ACK lysing buffer was required. 
 Human peripheral blood mononuclear cells 
Blood was obtained from healthy donors with ethics approval (Appendix 1). Whole blood 
was mixed with pre-warmed RPMI-1640 (Life Technologies Inc.) in a 1:1 ratio. The blood 
mixture was added to room-temperature Ficoll (GE Healthcare; Fairfield, CT, USA) in a 
1:2 (blood : Ficoll) ratio. Tubes were spun for 30 minutes at 913 × g and stopping was done 
without the aid of a break. The PBMC layer was carefully transferred to a new tube and 
washed with RPMI (Life Technologies Inc.) three times. With each wash, spin intensity 
decreased (514, 329, and 185 × g, respectively with break). Cells were resuspended in 
cRPMI and live cells were counted using Trypan Blue exclusion and diluted to the 
appropriate concentration as required for the indicated assay. 
2.12.2 T cell activation assay 
Cells were seeded at 2 × 105 cells per well in a 96-well plate. SAgs at indicated 
concentrations were added, and cells were incubated at 37°C with 5% CO2 for 18 hours. 
Cells were spun, and supernatant was removed and stored at -20°C until further 
experimentation. To assess activation, IL-2 was measured using ELISA (mouse IL-2 
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ELISA Ready-Set-Go! Kit [eBioscience Inc.] or human IL-2 ELISA Kit [BD Biosciences 
Inc.]) according to the manufacturer’s instructions. Briefly, Corning Costar 9018 (Corning) 
96-well high-bind plates were coated overnight at 4°C with appropriate capture antibody 
in supplied carbonate capture buffer. Plates were washed twice with wash buffer (PBS with 
0.05% [v/v] tween-20) and blocked for 2 hours at room temperature with assay diluent. 
Plates were washed as above and supernatant from stimulated cells was added (murine 
splenocyte supernatant added neat; human PBMC supernatant diluted 1:4 with assay 
diluent) and incubated at room temperature for one hour. Plates were washed as above 
three times, and detection cocktail was added (primary antibody-biotin and avidin-horse 
radish peroxidase conjugates were incubated together in assay diluent for 30 minutes prior 
to addition to 96-well plate) for one hour. Plates were washed five times as above, and 
supplied TMB was added for 15 minutes prior to colour change stoppage by addition of 1 
M H2SO4. All plates were read on a Synergy H4 plate reader (BioTek Instruments Inc.) by 
assessing absorbance at OD450 and subtracting OD570. Concentrations were determined by 
comparing supernatant concentrations to supplied standards, and limit of detection was 
3.125 ng mL-1 for murine IL-2 and 7.8 ng mL-1 for human IL-2.  
2.12.3 Flow cytometry 
Isolated cells were aliquoted at a concentration of 1 × 106 cells per tube, centrifuged at 450 
× g for 5 minutes, supernatant was removed, pellet was resuspended by racking and washed 
in 2 mL of FACS wash buffer (PBS supplemented with 2% [v/v] fetal bovine serum and 
0.01% [w/v] sodium azide). Cells were spun again as above, supernatant was removed, and 
cells were resuspended as above. Cells were incubated with appropriate concentrations of 
fluorophore-conjugated antibodies or cell viability dyes according to the manufacturer’s 
instructions for 30 minutes at 4°C or on ice protected from light. In low-light conditions, 
samples were washed three times as above, resuspended in 400 µL of FACS wash buffer, 
and read on an LSR II Flow Cytometer (BD Biosciences Inc.). 
2.12.4 T cell proliferation assay 
T cell proliferation was measured from human PBMCs using the CellTrace™ 
carboxyfluorescein succinimidyl ester (CFSE) cell proliferation kit (Thermo Fisher 
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Scientific Inc.) as per the manufacturer’s instructions. Briefly, 10 × 106 cells were 
resuspended in 37°C pre-warmed RPMI-1640 (Life Technologies Inc.) and a 5 mM 
CellTrace™ CFSE stock solution was created by diluting the stock solution with dimethyl 
sulfoxide (DMSO). The CFSE solution is added to the cells to generate a final 
concentration of 10 µM and cells are incubated in a water bath protected from light at 37°C 
for 10 minutes with gentle mixing at 5 minutes. Cell labelling was stopped by addition of 
30 mL of 4°C cRPMI, and the cell mixture was incubated on ice for 5 minutes. The cells 
were spun at 403 × g for 10 minutes and resuspended in cRPMI. Cells were aliquoted at 8 
× 105 cells per tube, and stimulated with varying concentrations of SAg or untreated 
control. Polymixin B was then added to a final concentration of 2 µg mL-1 and cells were 
incubated at 37°C with 5% CO2 for 5 days before flow cytometry analysis using a LSR II 
Flow Cytometer (BD Biosciences Inc.). 
 Multiplex cytokine array 
Cytokine and chemokine concentrations were determined from the cNT of HLA-DQ8 mice 
treated with LTF-2 (isotype control), GK1.5 (anti-mouse CD4), YT169.4 (anti-mouse 
CD8) or a combination of GK1.5 and YTS169.4 and infected with either S. pyogenes 
MGAS8232 or S. pneumoniae P1121. S. pyogenes infected HLA-DR4/DQ8 mice from 
wild-type SpeA and SEB vaccination groups, and a sham group, were also assessed. 
Uninfected HLA-DR4/DQ8 cNT homogenates were tested as a background control. 
Mutiplex cytokine array (Mouse Cytokine/Chemokine Array 31-Plex) was performed by 
Eve Technologies (Calgary, AB, Canada) and heat maps were generated using Matrix2png 
[461]. The data is shown as average cytokine response from 3-4 mice per group normalized 
to the highest concentration as 100% between all groups. Statistical analysis was completed 
by the appropriate test within groups (Appendix 4). 
 Statistical analysis 
Data was analyzed using unpaired Student’s t-test, one-way analysis of variance (ANOVA) 
with Dunnett’s multiple comparisons post-hoc test or two-way ANOVA with Tukey’s or 
Dunnett’s multiple comparison post-hoc test, as indicated. A value of P less than 0.05 was 
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determined to be statistically significant and all analyses were completed using Prism 
software (GraphPad Software, Inc.; La Jolla, CA, USA). 
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Chapter 3: Results  
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 Results 
 Generation and purification of wild-type and SpeA toxoid superantigens 
Wild-type SAg expression constructs, and select mutant toxoid constructs, were previously 
designed by members of the McCormick laboratory (Table 4). Constructs were generated 
in either the expression construct pET28a or pET41a, with either a TEV protease or 
thrombin cleavage site between the His6-Tag and the SAg gene (Figure 3A). Proteins were 
expressed by IPTG induction in E. coli BL21 (DE3), and purified from cell lysate using 
two-step nickel-affinity column chromatography (Figure 3B-D). For all SpeA mutant 
toxoids (except SpeAHEXA) that had not been previously generated, megaprimer PCR 
amplification was used with the appropriate primers (Table 5) (Figure 4A). SpeAHEXA was 
previously generated and published [437] without a TEV cleavage site between the His6-
Tag and the SAg gene. This construct was generated by amplifying the SpeAHEXA gene 
from the original construct using primers that added the nucleic acid sequence for a His6-
Tag, TEV protease cleave site with appropriate restriction enzyme sites for cloning into the 
pET28a expression vector (Table 5; Figure 4B). 
To supplement the previously designed MHC II binding site SpeA toxoid (SpeAY100A) 
[454], numerous other toxoids were generated using megaprimer PCR (Figure 4A) 
including: a TCR-binding interface toxoid (SpeAN20A); a toxoid containing both N20A and 
Y100A amino acid substitutions (SpeAN20A/Y100A); a further attenuate MHC II toxoid which 
combined the Y100A substitution with two additional substitutions at this interface (L41A 
and L42A; designated SpeATRI); as well as a toxoid that contained all the aforementioned 
substitutions (N20A/L41A/L42A/Y100A; designated SpeATETRA). The choice of the 
amino acid mutations were based upon previously published literature describing the 
attenuation of SpeA by the addition of these mutations [437,439,462]. SAg structures and 
relevant mutations were observed visually using PyMOL (The PyMOL Molecular 
Graphics System, Version 1.8 Schrödinger, LLC.). To generate the ribbon diagram, SEB 
in complex with TCR and MHC class II (4C56) [215] was used as a scaffold. The SpeA 
(1FNU) [203], HLA-DQ8 (1JK8) [463] and murine TCR vβ8 (1SBB) [220] constructs 
were superimposed onto the corresponding structures from the SEB ternary complex 
(Figure 5). 
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Figure 4. Polymerase chain methodology for the generation of SpeA toxoids. 
A. Mutant SpeA derivatives were generated by PCR amplification from speA housed in the 
pET28a expression plasmid. Forward and reverse primers spanned the area of interest and 
contained the appropriate nucleic acid changes to result in desired amino acid substitutions, 
with flanking upstream and downstream regions left complementary to the wild-type gene. 
Amplification of the construct using these primers resulted in a product containing the 
desired substitution. Restriction enzyme digestion with DpnI eradicated the parent plasmid 
and left only the desired toxoid construct, which could then be directly transformed into 
chemically-competent Escherichia coli and circularized by host DNA repair mechanisms. 
B. SpeAHEXA was provided by a collaborator and has been previously described [437]. The 
plasmid housing the speAHEXA gene did not have the desired purification or cleavage tags, 
so the gene was moved to a new expression plasmid using megaprimer PCR amplification. 
A forward primer containing the desired restriction enzyme cut site, 6x His-Tag and 
tobacco etch virus (TEV) protease cleavage site as well as 5′ sequence overlap to speAHEXA 
were used in combination with a reverse primer that had a second restriction enzyme cute 
site and 3′ overlap. Amplified gene product and empty pET28a expression plasmid were 
digested with indicated restriction enzymes, ligated together and transformed into desired 
chemically-competent E. coli strains. All transformants were selected for on media 
containing specific antibiotics and toxoid product sequences were confirmed using DNA 
sequencing. 
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Figure 5. Visualization of SpeA toxoid amino acid substitutions. 
A. Ribbon diagram cartoon of the SpeA crystal structure (grey) (1FNU) [203] in complex 
with murine TCR Vβ8 (yellow) (1SBB) [220] (α-chain, blue) and MHC class II HLA-DQ8 
(α-chain, red; β-chain, green) (1JK8) [463] was generated using the published 
TCR/SEB/MHCII trimolecular complex (4C56) [215] as a scaffold. B. and C. Inset box 
shows an up-close view of the SpeA immune complex interaction interface with 
highlighted amino acids (cyan) substituted in (B) SpeAHEXA 
(Q19H/N20D/L41A/L42A/D45N/C98S) and (C) SpeATETRA 
(N20A/L41A/L42A/Y100A). Images were generated with PyMOL (The PyMOL 
Molecular Graphics System, Version 1.8 Schrödinger, LLC.). 
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To generate purified SAg protein, cell lysate from induced bacterial strains that contained 
the desired SAg expression plasmids was applied to charged nickel resin column. His6-
tagged proteins were eluted from the column with increasing concentration of imidazole 
(Figure 3A). SDS-PAGE gels were used to determine fractions containing the desired 
protein which were subsequently dialyzed to remove imidazole and the His6-Tag was 
removed by addition of either autoinactivation-resistant His7::TEV [456] or thrombin 
depending on the construct (Table 4). Samples were again passed over a charged nickel 
column to removed purification tags and HIS7::TEV (Figure 3C). SAgs were isolated in 
wash or low imidazole concentrations and confirmed by size comparison on an SDS-PAGE 
(approximately 25kDa). Pure samples were dialyzed into a saline solution for future 
experimentation (Figure 3D). 
 Evaluation of superantigen function on immune cells 
3.2.1 Human PBMC proliferation, activation and anergy induced by wild-type 
superantigens 
The ability of purified wild-type SAgs to activate, cause proliferation and induce anergy in 
human PBMCs was assessed using flow cytometry (Figure 6). Cells were isolated from a 
healthy human donor and incubated with increasing concentrations of SAgs for 5 days. 
Proliferation was based on dilution of CFSE within dividing cells (Figure 6B), activation 
was based upon expression of CD25 (Figure 6C) and anergy was based upon expression 
of PD-1 (Figure 6D). All SAgs were able to activate, proliferate and induce anergy in both 
CD4+ and CD8+ cells, however, this donor was a low responder to SpeA and SSA. 
A second marker of activation – IL-2 – was also measured. Human PBMCs from the same 
donor were incubated with increasing concentrations of SAgs for 18 hours and IL-2 from 
culture supernatants were measured. Similar to the results above, it was demonstrated that 
all SAgs could activate human PBMCs, and it was noted that this donor was a low 
responder to SpeA and SSA (Figure 6E). 
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Figure 6. Activation of human T cells by recombinant streptococcal superantigens. 
Human peripheral blood mononuclear cells (PBMCs) were isolated from a healthy donor 
via Ficoll gradient centrifugation and stimulated with increasing concentrations of each 
streptococcal SAgs to assess their ability to proliferate, activate and induce markers of 
anergy in cells. A. Purified streptococcal SAgs were visualized using 12% SDS-PAGE. B 
– D. Human PBMCs were incubated with the indicated concentrations of SAg for five 
days. Cells were then analyzed by flow cytometry to assess (B) proliferation (CFSELow), 
(C) activation (CD25+) and (D) anergy (PD-1+) of CD3+ CD4+ or CD3+ CD8+ cells. Data 
represent singular values. (E) PBMCs were also incubated with indicated concentrations 
of SAg for 18 hours to assess activation based on supernatant IL-2 concentration as 
determined by ELISA. Data represent the mean of triplicate values. SAgs are colour-coded 
as indicated in the legend. 
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3.2.2 Evaluation of activation potential by wild-type superantigens on murine 
splenocytes 
The ability of SAgs to activate conventional C57Bl/6 and transgenic HLA-DR4/DQ8 mice 
was evaluated. Splenocytes from both mouse strains were stimulated with increasing 
concentrations of SAgs and culture supernatants were analyzed for IL-2 using ELISA. In 
contrast to humans, conventional C57Bl/6 mice were only stimulated by SpeH, SpeI and 
to a lesser extent SpeL, SpeM and SmeZ (Figure 7A). HLA-DR4/DQ8 transgenic mice 
were slightly more sensitive to the above mentioned SAgs, but were also stimulated by 
SpeA (Figure 7B). In comparison to human cells (Figure 6), the murine cells were 
stimulated to a much lower magnitude comparing overall concentrations of IL-2 in culture 
supernatant.  
 Confirmation of MHC II dependence during S. pyogenes infection 
Previous work from our laboratory has demonstrated the requirement for murine 
expression of human MHC II for efficient nasopharyngeal infection by S. pyogenes [449]. 
To confirm this finding, conventional C57Bl/6, HLA-DQ8 or HLA-DR4/DQ8 mice were 
infected with S. pyogenes MGAS8232. As previously shown, conventional C57Bl/6 mice 
were poorly infected by this strain of Group A Streptococcus, whereas mice expressing 
HLA-DQ8 (or -DR4/DQ8) had a significantly higher bacterial load at 48 hours (Figure 
8A). 
A second strain of S. pyogenes was tested for this MHC II dependence phenotype. S. 
pyogenes SF370 was inoculated into C57Bl/6 and HLA-DQ8 mice and nasopharyngeal 
bacterial load was assessed. Conventional C57Bl/6 mice were shown to harbor 
significantly less bacteria than their HLA-DQ8-exressing counterparts, confirming human 
MHC II dependence during infection for this strain of Group A Streptococcus (Figure 8B).  
 In vivo detection of superantigen expression 
Our laboratory has elucidated the importance of the SAg SpeA for nasopharyngeal 
infection by S. pyogenes MGAS8232 of HLA-DR4/DQ8 transgenic mice [449]. To 
determine if SpeA was expressed and could be detected by subsequent lymphocyte 
activation in vivo, mice were infected with either wild-type or S. pyogenes MGAS8232  
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Figure 7. Conventional and transgenic mouse T cell responses to streptococcal 
superantigens. 
Splenocytes from (A) conventional C57Bl/6 or (B) transgenic mice which lack endogenous 
murine MHC class II but express HLA-DR4 and HLA-DQ8 were stimulated with indicated 
concentrations of streptococcal SAgs for 18 hours. Culture supernatants were then 
analyzed for IL-2 using ELISA as a marker of T cell activation. Data represent the mean ± 
SEM of triplicate values from a single mouse. SAgs are colour-coded as indicated in the 
legend. 
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Figure 8. Efficient nasopharyngeal infection by S. pyogenes requires transgenic 
expression of human MHC class II molecules. 
Conventional C57Bl/6 or transgenic mice expressing the indicated human leukocyte 
antigen MHC class II molecules were intranasally infected with 108 CFU of either (A) S. 
pyogenes MGAS8232 or (B) S. pyogenes SF370 for 48 hours. Data points represent CFU 
from the cNT of individual mice. Horizontal bars represent the mean. Horizontal dotted 
line indicates the theoretical limit of detection. Significance determined by (A) one-way 
ANOVA with Tukey’s post-hoc test (***, P < 0.001) or (B) Student’s t test (*, P < 0.05). 
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ΔspeA and cervical lymph nodes were removed at 48 hours post-infection. SpeA-targeted 
lymphocytes were stained for activation markers and were compared to a non-targeted 
internal control. Using flow cytometry, live lymphocytes were gated first using forward 
and side scatter. Cells expressing CD3+ surface antigen were then gated. Expression of the 
activation marker CD25+ on SpeA-targeted T cell subset expressing the TCR Vβ8 chain 
was compared this to an internal control (TCR Vβ3 expressing T cells) (Figure 9A). It was 
demonstrated that between the two strains, there was no significant difference in the 
percentage of CD3+ TCR Vβ+ subsets (Figure 9B), however, there was a significant 
difference in the percentage of TCR Vβ8+ CD25+ T cells (targeted by SpeA) but not the 
non-SpeA targeted subset (TCR Vβ3) (Figure 9C). This data was also supplemented with 
cNT counts and which again demonstrated the importance of SpeA in our nasopharyngeal 
infection model (Figure 9D). 
 Anti-superantigen passive immunization protects mice from S. pyogenes infection 
To assess whether anti-SAg antibodies could be protective against S. pyogenes MGAS8232 
nasopharyngeal infection, a passive immunization experiment was designed. HLA-DQ8 
transgenic mice were administered hyper-immune serum from previously immunized 
rabbits containing antibodies to either SpeA or control serum containing anti-SpeC 
antibodies, as deletion of speC from S. pyogenes MGAS8232 had no effect on the infection 
phenotype [377]. After passive transfer, mice were infected with S. pyogenes MGAS8232 
and sacrificed 48 hours later (Figure 10A). Murine cNT was removed to assess 
nasopharyngeal bacterial burden and blood was drawn to examine antibody titres. Mice 
treated with anti-SpeA immune serum had significantly reduced bacterial load compared 
to control serum (Figure 10B). In addition, Western blot analysis demonstrated that the 
rabbit serum was specific for each SAg, and that the serum was not cross-reactive between 
SpeA and SpeC (Figure 10 C). As expected, protected mice had significantly higher anti-
SpeA antibodies present in their blood, and the lack of cross-reactivity was confirmed by 
ELISA (Figure 10 D and E). These results indicate that anti-SAg antibodies can be 
protective in a S. pyogenes nasopharyngeal infection model. 
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Figure 9. Detection of superantigen-dependent Vβ-specific T cell activation in vivo. 
Flow cytometric analysis of HLA-DR4/DQ8 cervical lymph node cells and cNT bacterial 
counts 48 hours post-infection with wild-type S. pyogenes MGAS8232 or MGAS823 
ΔSpeA (n ≥ 4 for each group). A. Cells were first gated on live lymphocytes using FSC 
and SSC followed by gating on CD3+ cells and either Vβ3+ CD25+ or Vβ8+ CD25+ cells. 
B. Percentages of Vβ3+ and V8+ subsets were compared between groups. C. Percentages 
of Vβ+ CD25+ cells were compared between groups. D. Data points represent CFU from 
the cNT of individual mice. Horizontal bars represent the mean. Horizontal dotted line 
indicates the theoretical limit of detection. Significance determined by Student’s t test (**, 
P < 0.01; ***, P < 0.001). 
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Figure 10. Passive immunization with hyper-immune anti-SpeA rabbit serum reduces 
the burden of S. pyogenes MGAS8232 in the nasopharynx. 
A. Passive immunization schedule. B. Nasal challenge of HLA-DQ8 transgenic mice with 
108 CFU S. pyogenes MGAS8232 after passive immunization with rabbit anti-SpeA or 
anti-SpeC serum. Data points represent CFU from the cNT of individual mice at 48 hours. 
Horizontal bars represent the mean. The horizontal dotted line indicates the theoretical limit 
of detection. C. Recombinant SAg (15% SDS-PAGE; top panel) and Western blot (bottom 
two panels). D and E. Serum IgG antibody titres determined using ELISA from HLA-DQ8 
mice (n ≥ 4) passively immunized with indicated treatment. Plates were coated with 100 
µL of 10 µg mL-1 SpeA (D) or SpeC (E). Bars represent the mean ± SEM. Colours 
correspond throughout the figure as follows: α-SpeA, red; α-SpeC, yellow. Significance 
determined by unpaired Student’s t test (*, P < 0.05; **, P < 0.01).  
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 Evaluation of differing SpeA concentrations for vaccine dosage 
Since it was previously determined that SpeA was required for efficient murine 
nasopharyngeal infection by S. pyogenes MGAS8232 and that its activating potential could 
be detected in vivo, we decided to target this SAg for our vaccination studies. To determine 
an optimal concentration for SAg vaccination, three groups of HLA-DR4/DQ8 transgenic 
mice were administered different concentrations (100 ng, 1 µg or 10 µg) of SpeA with 
alum adjuvant. Mice received subcutaneous injections under isoflurane anesthetic on day 
0, 14 and 28 with blood being drawn via saphenous vein on day 42 to assess antibody titres 
(Figure 11A). Weight was also monitored on day 0 prior to the first injection, and on day 
7, 21 and 42 to determine if there was a detrimental effect on weight gain by wild-type 
SpeA injections. Mice were then infected with S. pyogenes MGAS8232, and the bacterial 
burden was assessed. The only vaccination dose to show a significant protective effect was 
1 µg although there were trends at both the low and the high doses (Figure 11B). 
Interestingly, there was no statistical difference in anti-SpeA IgG titres either, however, an 
increased trend was noted in the 10 µg treatment group (Figure 11C). Consistent with the 
non-invasive nature of the model [449], S. pyogenes was below the limit of detection in the 
blood, spleen, kidneys, liver and heart (Figure 12A-E). Control lungs had two cases of S. 
pyogenes detection above the limit of detection, but these counts were not statistically 
different compared to any other treatment group (Figure 12F). All treatment group weights 
increased during the vaccine regimen, and there was no difference between groups (Figure 
12G). 
 Wild-type superantigen vaccination protection stems from reduced and 
unresponsive T cell subsets 
After it was concluded that 1 µg of SpeA was the optimal tested dose that reduced murine 
nasopharyngeal bacterial burden compared to our control group, this concentration was 
used for the remainder of our vaccine experimentation. The observation that significant 
antibody titres were not present in our protective SpeA dose (Figure 11C) made us 
consider an alternative explanation for this protective phenotype. SAgs are known to 
interact with both T cells and antigen presenting cells; however, their impact on T cells has 
been more rigorously studied. Thus, we sought to examine the effects of our wild-type  
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Figure 11. Assessing effective dose of SpeA superantigen vaccination. 
A. Superantigen vaccination protocol. B. HLA-DR4/DQ8 transgenic mice were vaccinated 
with the SpeA at the indicated concentration and intranasally infected with 108 CFU S. 
pyogenes MGAS8232 for 48 hours post-vaccination. Data points represent CFU from the 
cNT of individual mice. Horizontal bars represent the mean. Horizontal dotted line 
indicates the theoretical limit of detection. C. Serum was collected 24 hours prior to 
infection and used to assess antibody titre using ELISA (n ≥ 4). Data represented as the 
mean ± SEM. Significance determined by one-way ANOVA with Dunnett’s post-hoc test 
(*, P < 0.05). 
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Figure 12. Nasopharyngeal infection by S. pyogenes MGAS8232 is not invasive and 
vaccination with SpeA does not alter weight gain. 
A – F. HLA-DR4/DQ8 transgenic mice were vaccinated three times over a 28-day period 
and infected two weeks post-vaccination with 108 CFU of S. pyogenes MGAS8232. Mice 
were sacrificed 48 hours post-infection and indicated organs were removed, homogenized 
and plated to assess bacterial burden. Data points represent CFU indicated organs of 
individual mice. Horizontal bars represent the mean. Horizontal dotted line indicates the 
theoretical limit of detection. A one-way ANOVA with Dunnett’s post-hoc test was used 
to evaluate significance. G. Mice (n ≥ 4) were weighed on indicated days to assess impact 
of SAg vaccination. Data represented as the mean ± SEM. Significance was assessed using 
a two-way ANOVA with Dunnett’s post-hoc test. 
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SpeA vaccine treatment on Vβ8+ T cells known to be targeted by SpeA. Two additional 
SAg controls were included in these analyses. Staphylococcal enterotoxin B (SEB) is a 
SAg that is produced by S. aureus, and also primarily targets Vβ8+ T cells. SpeC is a 
streptococcal SAg that is unable to activate murine T cells due to an inability to interact 
with murine TCRs [464] and was thus used as a negative control. SEB and SpeC were 
purified (Figure 13A) and their ability to stimulate transgenic HLA-DR4/DQ8 mouse 
splenocytes was assessed. It was confirmed that SEB has similar stimulation potential to 
SpeA, and SpeC had no stimulation potential at the highest concentration tested (Figure 
13B). 
Following the above mentioned vaccination protocol in our transgenic HLA-DR4/DQ8 
mice, S. pyogenes MGAS8232 nasopharyngeal bacterial burden was assessed. Mice treated 
with either SpeA or SEB wild-type SAgs had significantly reduced bacterial loads 
compared to both control groups (Figure 13C). In order to exclude the possibility of 
antibody-mediated protection, anti-SpeA IgG titres were assessed across all groups and it 
was shown no treatment generated titres above our saline/alum adjuvant control (Figure 
13D). Splenocytes from the above mentioned groups were analyzed by flow cytometry to 
assess the impact of SAg vaccination on specific TCR Vβ subsets. CD3+ TCR Vβ8+ and 
TCR Vβ3+ (internal control) T cells subsets were compared between groups. There was a 
relative decrease of detectable TCR Vβ8+ T cells in SpeA and SEB treated mice compared 
to control treated mice, but no difference in TCR Vβ3+ T cells (Figure 14A and B). T cell 
responsiveness was also tested by SAg stimulation of vaccinated mouse splenocytes. 
Splenocytes from control-, SpeA- and SEB-vaccinated mice were processed and re-
stimulated with either TCR Vβ8+ targeting SAgs (SpeA and SEB) or streptococcal 
mitogenic exotoxin Z (SmeZ), a SAg that targets TCR Vβ11+ T cells (an unaffected T cell 
subset) that was used as an internal control. Mice treated with either TCR Vβ8+-targeting 
SAg had an impaired ability to be stimulated by TCR Vβ8+-targeting SAgs compared to 
control-treated mice (Figure 14C and D). All groups were able to be stimulated by TCR 
Vβ11+-targeting SAg SmeZ; however, SpeA and SEB treated mice seemed to respond 
better to this SAg (Figure 14E). This data suggests that wild-type SpeA- and SEB- 
vaccinated mice had impaired TCR Vβ8+ T cells, but other subsets (i.e. Vβ11) remained 
responsive. This impairment also correlated with in vivo protection from S. pyogenes  
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Figure 13. Vaccination with wild-type TCR Vβ8-targeting superantigens is protective 
against nasopharyngeal infection by S. pyogenes MGAS8232 but does not appear to 
be antibody mediated. 
A. Purified SAgs visualized using 12% SDS-PAGE. B. Activation assay measuring the 
ability of purified SAgs to stimulate HLA-DR4/DQ8 murine splenocytes as determined by 
IL-2 production. Data represented as the mean ± SEM of triplicate values from a single 
mouse. C. HLA-DR4/DQ8 mice were vaccinated with either a saline control and adjuvant 
or the indicated SAgs as previously described. Mice were intranasally infected with 108 
CFU of S. pyogenes MGAS8232 and sacrificed 48 hours later. Data points represent CFU 
from the cNT of individual mice. Horizontal bars represent the mean. Horizontal dotted 
line indicates the theoretical limit of detection. D. Serum was collected 24 hours prior to 
infection and used to assess antibody titre using ELISA (n ≥ 4). SpeA cNT and serum IgG 
levels are the same as those reported in Figure 11 for mice vaccinated with 1 µg of SpeA. 
Colours correspond to: control, black; SpeA, red; SEB, blue and SpeC, yellow. Data 
represented as the mean ± SEM. Significance determined by one-way ANOVA with 
Dunnett’s post-hoc test (***, P < 0.001). 
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Figure 14. SpeA- and SEB-vaccinated mice have impaired Vβ8+ T cells. 
A and B. Flow cytometric analysis of splenocytes at day 43 post-SAg vaccination (n = 4 
for each group). A. Representative flow plots for each treatment group stained for CD3 
(APC) and either Vβ3 or Vβ8 (FITC). Staining of Vβ3 and Vβ8 are from the same mouse. 
Each sample was first gated on lymphocyte population based on FSC and SSC before 
gating on CD3+ Vβ+ population. B. Percentage of CD3+ Vβ3+ or CD3+ Vβ8+ T cell subset 
for each treatment group (control, black; SpeA, red; SEB, blue). Data are shown as mean 
± SEM. Significance determined by two-way ANOVA with Dunnett’s multiple 
comparison post-hoc test (*, P < 0.05; ***, P < 0.001).C – E. HLA-DR4/DQ8 mouse 
splenocyte IL-2 activation assay post vaccination with control (●), SpeA (▲) or SEB (▼) 
(n = 3 for each group). Treated mouse splenocytes were stimulated with increasing 
concentrations of SAgs targeting specific TCR Vβ subsets (C) SpeA, Vβ8; (D) SEB, Vβ8; 
(E) SmeZ, Vβ11. Stimulation occurred for 18 hours and culture supernatants were analyzed 
for IL-2 using ELISA as a readout for T cell activation. Data is shown as the mean ± SEM 
of triplicate values from each mouse. 
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nasopharyngeal infection indicating that wild-type vaccine protection likely stems from 
rendering specific SAg-targeted T cell subsets unresponsive. 
 Superantigen toxoid vaccination can induce protective antibodies in vivo 
3.8.1 Vaccination with SpeAY100A elicits a protective but bimodal phenotype 
Discovery that passive immunization with anti-SAg antibodies could reduce S. pyogenes 
bacterial load in a murine nasopharyngeal infection model prompted us to test whether 
vaccination with SAgs could generate protective antibodies. However, vaccination with 
wild-type SpeA did not generate significant anti-SAg antibodies (Figure 13D) whereas 
protection from this vaccination procedure stemmed from rendering a specific T cell subset 
unresponsiveness (Figure 14), indicating that an alternative approach must be taken to 
generate protective anti-SAg antibodies. To assess whether attenuated SAgs would be able 
to generate antibodies upon vaccination, a previously generated SpeA variant with a 
mutated MHC II interface – SpeAY100A – [454] was used. It was first shown that SpeAY100A 
had reduced capacity to activate HLA-DR4/DQ8 murine splenocytes (as determined 
through IL-2 production) compared to its wild-type counterpart (Figure 15A). Next, 
transgenic HLA-DR4/DQ8 mice vaccinated with SpeAY100A had significantly reduced 
bacterial load in their nasopharynx when infected with S. pyogenes MGAS8232 (Figure 
15B). Upon assessment of antibody titres, it was discovered that despite the protective 
effects in mice, only a fraction (3/5) elicited a high anti-SpeA IgG antibody response 
(Figure 15C). Flow cytometric analysis of SpeAY100A-vaccinated mouse splenocytes 
indicated that there was no reduction of Vβ8+ T cells compared to control-vaccinated mice 
(Figure 15D). However, we were able to show, using our previously described T cell 
responsiveness assay (Figure 14C-E), that in circumstances where vaccination with 
SpeAY100A resulted in minimal anti-SpeA antibodies production (Figure 16A), Vβ8+ T 
cells were poorly responsive, similar to what was shown with wild-type SpeA-vaccinated 
mice (Figure 16B and C). In contract, SpeAY100A-vaccinated mice that generated high anti-
SpeA antibody titres had more responsive Vβ8+ T cells similar to control-vaccinated mice 
(Figure 16B and C). Both low and high anti-SpeA antibody producing mouse splenocytes 
had similar responsiveness to the TCR Vβ11+-targeting SAg SmeZ (Figure 16D) which 
was used as an internal control to indicate that irrelevant TCR Vβ subsets were not  
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Figure 15. Vaccination with either SpeAY100A or SpeAHEXA does not yield consistent 
antibody-mediated protection. 
A. Activation assay measuring ability of wild-type or toxoid SAg to stimulate HLA-
DR4/DQ8 murine splenocytes as determined by IL-2 production. Data represented as the 
mean ± SEM of triplicate values from a single mouse. B. HLA-DR4/DQ8 mice were 
vaccinated with either a saline control or the indicated SAg toxoid. Mice were intranasally 
infected with 108 CFU of S. pyogenes MGAS8232 and sacrificed 48 hours later. Data 
points represent CFU from the cNT of individual mice. Horizontal bars represent the mean. 
Horizontal dotted line indicates limit of detection. C. Serum was collected 24 hours prior 
to infection and used to assess IgG antibody titres using ELISA (n ≥ 5). Data represented 
as the mean ± SEM. Significance determined by one-way ANOVA with Dunnett’s post-
hoc test (*, P < 0.05; **, P < 0.01). D. Flow cytometric analysis of splenocytes at day 43 
post-SAg vaccination (n ≥ 3 for each group). Treatment groups were stained for CD3 
(APC) and either Vβ3 or Vβ8 (FITC). Each sample was first gated on live lymphocyte 
population based on FSC and SSC before gating on CD3+ Vβ+ population. Data represents 
percentage of CD3+ Vβ3+ or CD3+ Vβ8+ T cell subset for each treatment group. Data are 
shown as mean ± SEM. Control Vβ percentage data is replicated from Figure 14B. 
Statistical significance was assessed by two-way ANOVA with Dunnett’s multiple 
comparison post-hoc test. 
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Figure 16. SpeAY100A vaccination elicits a bimodal antibody phenotype. 
A. Two HLA-DR4/DQ8 mice were vaccinated with SpeAY100A and antibody titre against 
wild-type SpeA was determined by ELISA. B – D. The SpeAY100A-vaccinated HLA-
DR4/DQ8 mouse splenocytes were stimulated separately with increasing concentrations of 
two TCR Vβ8+-targeting SAgs, SpeA (B) and SEB (C), and a TCR Vβ11+-targeting SAg, 
SmeZ (D), as an internal control. Incubation occurred for 18 hours and IL-2 was measured 
from splenocyte culture supernatants as a marker for T cell activation. For comparison 
purposes, control (●) and SpeA (●) curves were added from Figure 14C-E. The SpeAY100A-
vaccinated mice with low antibody titre (■) and with high antibody titre (▲) were assessed 
for their ability to respond to exogenous SAgs (n = 1 repeated in triplicate for each group). 
Data is shown as the mean. 
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impacted by the vaccination protocol. This data suggests that vaccination with SpeAY100A 
can result in two protective phenotypes: a low anti-SpeA antibody titre with unresponsive 
TCR Vβ8+ T cells that protects similarly to wild-type SpeA vaccination, or a high anti-
SpeA antibody titres where T cell subsets are responsive and protection is antibody-
mediated. 
3.8.2 SpeAHEXA induces high antibody titres but is not consistently protective 
Our previous finding that SpeAY100A was still able to impair T cell responsiveness led us to 
attempt vaccination with a further attenuated SpeA variant. It was previously shown that a 
SpeA toxoid with six amino acid substitutions – SpeAHEXA – was protective in a rabbit 
model of STSS [437]. We sought to determine if vaccination with this molecule would be 
protective in our streptococcal murine nasopharyngeal infection model. SpeAHEXA was 
unable to activate HLA-DR4/DQ8 transgenic murine splenocytes at even the highest 
concentration tested (Figure 15A). Upon vaccination, only 50% of mice had reduced 
bacteria load in the cNT (Figure 15B), despite all mice having consistently high anti-SpeA 
antibody titres (Figure 15C). Assessment of T cell subsets using flow cytometry revealed 
no differences in Vβ3+ or Vβ8+ T cell subsets compared to control-vaccinated mice (Figure 
15D). This data demonstrates that the six amino acid substitutions of SpeAHEXA render it 
unable to activate T cells and consistently generate high anti-SpeA antibody titres in vivo; 
however, the antibodies generated were not reliably protective in our model of S. pyogenes 
nasopharyngeal infection. 
3.8.3 SpeATRI generates high antibody titres and is consistently protective 
Due to the bimodal protection phenotype of SpeAY100A and the ~50% efficacy of SpeAHEXA 
when used as a vaccine, a minimalistic approach was taken to generating an inactive SpeA 
toxoid that contained as few amino acid substitutions as possible and provided consistent 
protection and high antibody titres. Previous data has shown that the asparagine at position 
20 is crucial for SpeA interacting with the TCR [437,462], and the leucine residues at 
positions 41 and 42 have been previously shown to be important for interaction with MHC 
II [437,439]. These residues were thus mutated to alanine using primer-based site-directed 
mutagenesis both separately and in tandem to generate four new mutants. SpeAN20A, 
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SpeAN20A/Y100A, SpeATRI (L41A/L42A/Y100A) and SpeATETRA 
(N20A/L41A/L42A/Y100A) each were shown to have drastically reduced capacity to 
activate murine splenocytes compared to wild-type SpeA (Figure 17A). Each of these 
mutants was then tested in our vaccination regimen to assess protection from S. pyogenes 
nasopharyngeal challenge (Figure 17B) and antibody titres (Figure 17C and D). 
Interestingly, despite all mutants having reduced superantigenic activity, only SpeATRI 
generated both consistent protection and high anti-SpeA IgG antibody titres. SpeAN20A 
failed to both protect mice or generate an anti-SpeA antibody response. SpeAN20A/Y100A had 
~50% protection rate and a variable anti-SpeA IgG profile. The mice that were protected 
from infection by SpeAN20A/Y100A vaccination were shown to have a higher anti-SpeA IgG 
titre, whereas mice with higher bacterial load had low anti-SpeA antibody titres. These data 
suggest that when this SpeAN20A/Y100A vaccination does yield high anti-SpeA antibody 
titres, the mice are protected (Appendix 3). Vaccination with SpeATETRA, which contains 
all of the mutations of SpeATRI in addition to N20A, trended to produce enhanced, but not 
significantly higher anti-SpeA IgG antibody titres (Figure 17C) with inconsistent 
protection (5/8) (Figure 17B). In conclusion, the most successful toxoid that consistently 
generated high anti-SAg antibody titres was SpeATRI that had amino acid substitutions only 
within the MHC II binding interface. 
 Depletion of CD4+ and CD8+ T cells reduce S. pyogenes burden 
Our finding that vaccination with wild-type SpeA and SEB generated unresponsive T cell 
subsets that ultimately led to protection in these mice led us to assess whether these cells 
were required for infection establishment by S. pyogenes. To determine this, we sought to 
deplete specific T cell subsets using a previously published depletion strategy [458] 
(Figure 18A) and subsequently assess the impact on nasopharyngeal infection. To confirm 
the depletion potential of these antibodies, transgenic HLA-DQ8 mice were administered 
three doses of T cell-depleting antibody, or isotype control, and cervical lymph nodes were 
subjected to flow cytometry to assess T cell subset abundance. Lymphocytes were gated 
using forward and side scatter, and CD4+ and CD8+ T cell subsets were analyzed (Figure 
18B). Compared to the isotype control, administration of T cell-depleting antibodies  
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Figure 17. Further mutations within the MHC II binding interface of SpeA generates 
high IgG antibody titres and is protective. 
A. Activation assay measuring ability of wild-type or toxoid SAgs to stimulate HLA-
DR4/DQ8 murine splenocytes as determined by IL-2 production. Data represented as the 
mean ± SEM of triplicate values from a single mouse. B. HLA-DR4/DQ8 mice were 
vaccinated with a saline control or the indicated SpeA toxoid as previously described. Mice 
were intranasally infected with 108 CFU of S. pyogenes MGAS8232 and sacrificed 48 
hours later. Data points represent CFU from the cNT of individual mice. Horizontal bars 
represent the mean. Horizontal dotted line indicates the theoretical limit of detection. C. 
Serum was collected 24 hours prior to infection and used to assess IgG antibody titres using 
ELISA (n ≥ 3). Data is represented as the mean ± SEM. Significance determined by one-
way ANOVA with Dunnett’s post-hoc test (*, P < 0.05; **, P < 0.01). SpeA IL-2 activation 
assay (Figure 15), cNT and IgG (Figure 11; designated 1 µg therein) are repeated values; 
IL-2 activation assay, cNT and Ig data for control, SpeAY100A and SpeAHEXA data are 
repeated from Figure 15. 
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Figure 18. Depletion of CD4+ and CD8+ T cells reduces S. pyogenes nasopharyngeal 
bacterial load. 
A. T cell depletion protocol.  B and C. Flow cytometric analysis of cervical lymph node 
populations at day 0 post T cell depletion (n = 3 per group). B. Representative flow plots 
for each treatment group stained for CD4 (APC-efluor 780) and CD8 (PE). Each sample 
had the lymphocytes first gated upon using FSC and SSC. C. Percentage of CD4+ and 
CD8+ cells to total lymphocyte population in both treatment groups. Data are shown as 
mean ± SEM. Significance determined by Student’s t test (***, P < 0.001). D. Nasal 
challenge of transgenic mice expressing HLA-DQ8 with 108 CFU S. pyogenes MGAS8232 
post-injection with indicated treatments. Data points represent CFU from the complete 
nasal turbinates (cNT) of individual mice 48 hours post-infection. Horizontal bars represent 
the mean. The horizontal dotted line indicates limit of detection. Significance determined 
by one-way ANOVA with Dunnett’s multiple comparisons post-hoc test (*, P < 0.05; **, 
P < 0.01). 
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significantly reduced the CD4+ and CD8+ subsets (Figure 18C). Next, mice were again 
administered T cell-depleting antibodies as described above, but were infected with S. 
pyogenes MGAS8232 for 48 hours. Mice were then sacrificed and cNT bacterial load was 
assessed. Depletion of CD8+ alone, but not CD4+ T cells significantly reduced S. pyogenes 
nasopharyngeal bacterial load; however, the greatest reduction was observed upon 
depletion of both subsets (Figure 18D). These results support the requirement for CD4+ 
and CD8+ T cell subsets during S. pyogenes nasopharyngeal infection.  
 CD4+ and CD8+ T cell subset depletion has no impact on S. pneumoniae P1121 
bacterial load 
To determine whether the above-mentioned T cell depletion phenotype was specific to S. 
pyogenes, another human-specific nasopharyngeal colonizer – Streptococcus pneumoniae 
– was tested for its ability to infect T cell-depleted mice. We first assessed whether the 
ability of S. pneumoniae to infect the nasopharynx of mice was human MHC II-dependent. 
Both conventional C57Bl/6 and transgenic HLA-DR4/DQ8 mice were intranasally 
infected with S. pneumoniae P1121 and bacterial load in the cNT was evaluated. It was 
demonstrated that both strains of mice had high bacterial load 48 hours post-infection; 
however, HLA-DR4/DQ8 mice did have a statistically higher bacterial yield (Figure 19A). 
It was also shown that bacterial load was below the detectable limit in all but one lung 
sample (Figure 19B) and in the blood (Figure 19C). The cNT bacterial burden was also 
comparable to those seen in S. pyogenes infected HLA-DQ8 transgenic mice (Figure 8A). 
Next, the impact of T cell depletion was measured. HLA-DQ8 mice were treated with T 
cell depleting or isotype control antibodies as above, and mice were infected intranasally 
with S. pneumoniae P1121. T cell depletion had no impact on infection (Figure 20A). To 
ensure that the inoculation dose did not result in pneumonia or bacteremia, lung and blood 
samples were plated for bacterial enumeration. It was determined that only one T cell 
depleted mouse had bacteria above the detectable limit in the lungs but this was not 
significantly different compared with control mice (Figure 20B). There were no bacteria 
in the blood above the detectable limit (Figure 20C). This data supports the notion that the 
conventional T cell subset dependence phenotypes observed in S. pyogenes MGAS8232 
are not common to all human upper respiratory tract-infecting organisms. 
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Figure 19. C57Bl/6 and HLA-DR4/DQ8 nasopharyngeal infection by S. pneumoniae. 
Conventional C57Bl/6 or HLA-DR4/DQ8 mice were intranasally infected with 107 CFU 
of S. pneumoniae P1121 for 48 hours. Mice were then sacrificed and cNT (A), lung (B) 
and blood (C) were extracted, processed and plated for bacterial enumeration. Data points 
represent CFU from indicated tissue of individual mice 48 hours post-infection. Horizontal 
bars represent the mean. The horizontal dotted line indicates limit of detection. 
Significance was determined by Student’s t test (*, P < 0.05). 
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Figure 20. Depletion of conventional T cells has no impact on S. pneumoniae 
nasopharyngeal infection. 
HLA-DR4/DQ8 mice were treated with isotype control (black) or α-CD4 (GK1.5) and α-
CD8 (YTS 169.4) depleting antibodies (pink) and intranasally infected with 107 CFU S. 
pneumoniae P1121. Mice were sacrificed 48 hours later and cNT (A), lung (B) and blood 
(C) were isolated, processed, and plated for bacterial enumeration. Data points represent 
CFU from indicated tissue of individual mice 48 hours post-infection. Horizontal bars 
represent the mean. The horizontal dotted line indicates the theoretical limit of detection. 
Statistical analysis was completed using Student’s t test. 
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 Responsive T cells are required for robust cytokine response during S. pyogenes 
nasopharyngeal infection 
To assess the cytokine and chemokine environment during SAg-rendered 
unresponsiveness and T cell depletion followed by infection, supernatants from the cNT of 
treated and infected mice were analyzed by multiplex cytokine array to test for the presence 
of 32 cytokines. Statistical analyses were completed on individual cytokines within 
treatment and infection groups. Any cytokine that showed a significant difference within 
any of the treatment groups was included in the heat map for all groups. To compare the 
cytokines between groups, the heat map displays individual cytokine concentrations 
between all treatment groups which were normalized so that the highest concentration was 
100% (Figure 21). Quantitative data is shown in Appendix 4. For S. pyogenes infections, 
the most robust cytokine response can be seen in the sham-vaccinated (saline plus alum 
adjuvant) or the isotype control (LTF-2) treated mice and includes: Th1-type cytokines 
(TNFα, IL-1β and IL-12 [p70]); Th2-type cytokines (IL-4); Th17-type cytokines (IL-6 and 
IL-17); chemokines (KC, IP-10, MCP-1, MIP-1α, MIP-1β, MIP-2 and LIF); and growth 
factors (G-CSF and M-CSF) (Figure 21B and C; Appendix 4). Conversely, mice with T 
cell subsets that were unresponsive to SpeA, either by wild-type SpeA or wild-type SEB 
vaccination, or treatment with CD4 (GK1.5) and CD8 (YTS 169.4) T cell-depleting 
antibodies (Figure 21B and C) had cytokine profiles similar to uninfected mice (Figure 
21A). These results are in stark contrast to mice treated with isotype control or CD4 and 
CD8 T cell-depleting antibodies and infected with S. pneumoniae (Figure 21D). T cell 
depleted mice infected with S. pneumoniae demonstrated higher cytokine/chemokine 
responses compared to isotype control treated mice. These elevated molecules included: 
Th1-type cytokines (TNFα, IL-1α and IL-12 [p70]); Th2-type cytokines (IL-4); Th17-type 
cytokines (IL-6 and IL-17); and chemokines (KC, IP-10, MCP-1, MIG and LIF) (Figure 
21D). There were also numerous cytokines that were either not different between any 
groups or did not conform to any obvious trends (Appendix 4). These results suggest that 
the presence of responsive T cells plays an important role in modulating the 
nasopharyngeal cytokine environment during S. pyogenes infections, which differs greatly 
from that during infection with S. pneumoniae. 
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Figure 21. Impact of superantigen-vaccination and T cell depletion on the murine 
nasopharyngeal cytokine microenvironment following infection by S. pyogenes 
MGAS8232. 
HLA-expressing mice were either uninfected (A), vaccinated (B) or underwent T cell 
depleting antibody treatment (C and D) prior to infection with either 108 CFU of S. 
pyogenes MGAS8232 (B and C) or 107 S. pneumoniae P1121 (D) for 48 hours. Mice were 
sacrificed and supernatant from cNT homogenates were procured for cytokine and 
chemokine analysis. Data shown represents the mean cNT cytokine response that displayed 
significant differences within any group. Values for each individual cytokine were 
normalized to have the highest cytokine value as 100% (n ≥ 3 mice per group). 
Corresponding quantitative data and statistical analyses are shown in Appendix 4. 
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 Discussion 
The primary barrier to preventing the greater than 500,000 deaths cause by GAS each year 
[4] is the lack of a safe and effective vaccine. Although this topic has been extensively 
studied for decades, there are numerous deterrents which have prevented this crucial 
prophylactic from being developed, including the lack of monetary incentive (due to this 
organism being a primary burden on developing, low income nations) and the potential for 
developing a cross-reactive immune response upon immunization with bacterial 
components leading to autoimmune sequelae [433,465]. The most promising vaccine 
candidate thus far is a multivalent M protein-based vaccine that targets 26 of the most 
common pharyngitis, invasive and rheumatogenic serotypes, and this vaccine has now 
undergone phase I and II clinical trials [419] and a reformatted 30-valent vaccine has 
undergone phase I trials [418,433]. The choice to target the M protein as a potential vaccine 
component stems from experiments completed over 50 years ago in pioneering studies by 
Rebecca Lancefield who demonstrated type-specific protective immunity in mice and 
subsequently showed that in humans, bactericidal M protein antibodies persisted for years 
after GAS infection [412].  Despite these findings, an overarching concern with M protein-
based vaccines is that there are over 200 known streptococcal emm-types with varying 
distributions worldwide [49], presenting a possible complication of vaccine coverage and 
the likelihood of selecting for emm-types not present in the vaccine. Recent findings have 
shown that the 30-valent vaccine would protect against the majority of invasive- and 
pharyngitis-associated emm-types in North America and Europe [14,58,421,422] and does 
produce cross-reactive antibodies that target other emm-types [423,424]. This furthers the 
potential of M protein-based vaccines, but it is considered unlikely that a universally 
protective vaccine will ever arise from just targeting the M protein. Our belief is that a 
vaccine that targets multiple bacterial components that are known to be crucial to the 
establishment and/or maintenance of infection and survival of the organism in vivo would 
be a more successful candidate. 
Streptococcal infection of the throat, skin and/or mucosa often precedes autoimmune 
sequelae [12,29,466], which results in the largest burden of GAS-associated disease 
[4,467]. Therefore, prevention of bacterial colonization and infection would largely prevent 
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this disease burden. Previous findings from our laboratory that GAS SAgs are required for 
efficient acute nasopharyngeal infection [377], and our demonstration herein that SAgs are 
expressed during infection establishment (Figure 9) led us to consider these toxins as 
potential vaccine candidates. One major benefit to the use of SAgs as vaccine candidates 
is that there are only 11 known Group A streptococcal SAgs [187]. This makes the 
generation of a pan-SAg vaccine more feasible compared to targeting the greater than 200 
streptococcal emm-types. There is also data showing that administration of IVIG, which 
contain SAg-neutralizing antibodies [468], may reduce patient mortality in some settings 
[22,469,470], providing support for anti-SAg antibody-mediated protection against S. 
pyogenes in humans. Although it has been noted that numerous SAgs have multiple alleles, 
these generally differ in just a few amino acids [245], and thus it is probable that antibodies 
generated against one allele would cross-react. The one documented exception to this is 
SmeZ, in which there are over 50 variants [187]. Current analysis indicated that all tested 
variants still target human TCR Vβ8+ cells, and those that do not are truncated and inactive 
[205], which indicates that if antibodies towards the TCR-targeting interface of SmeZ 
could be generated, this would likely neutralize most, if not all, active SmeZ variants. 
Our vaccine analysis focused on SpeA, the only critical SAg in our human transgenic 
mouse model of S. pyogenes MGAS8232 upper respiratory tract infection [377]. A goal of 
this project was thus to produce a SpeA-based vaccine that generated antibody-mediated 
protection in our nasopharyngeal infection model. Previous studies have used SpeA toxoids 
as vaccine candidates [437,439] in severe and invasive disease, but not in the context of 
nasopharyngeal infection or other non-invasive models. Our passive immunization 
experiments show conclusively that anti-SpeA antibodies can be protective in S. pyogenes 
nasopharyngeal infection (Figure 10). Although treatment with wild-type SpeA was 
protective (Figure 13C), this was not antibody-mediated (Figure 13D), and instead was 
due to rendering TCR Vβ8+ T cells unresponsive (Figure 14). Although protective in our 
animal model, vaccinating with wild-type SAgs would never be plausible for human use. 
This would primarily be due to the fact that SAgs are potent toxins that are capable of 
causing severe diseases – such as TSS – at extremely low concentrations and could also 
potentially drive an autoimmune response. Also, protection stemmed from rendering T cell 
subsets unresponsive, and thus individuals receiving a wild-type SAg vaccination may 
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invoke some level of protection against S. pyogenes infection, but may also be more 
susceptible to infections normally controlled by functioning T cells, such as viral infection. 
Nevertheless, this finding led us to pursue testing of attenuated SpeA toxoids in our 
vaccination model. Previously described mutants SpeAY100A [454] and SpeAHEXA [437] 
that were tested in this vaccination model did not satisfy the above mentioned criteria due 
to protection stemming partially from unresponsive T cells  (Figure 15B and 16) or 
consistent, yet non-protective anti-SpeA antibody titres (Figure 15B and C), respectively. 
These findings led us to further analyze SpeA TCR and MHC class II binding site mutants, 
whereby we determined a further attenuated MHC II binding site mutant, SpeATRI, was 
able to generate consistently high anti-SpeA antibody titres and consistent protection 
(Figure 17B and C). 
Mutation of asparagine at position 20 impacts the SpeA-TCR Vβ interacting interface 
(Figure 5C). Interestingly, incorporation of this amino acid substitution alone or in tandem 
with other substitutions generated a SpeA toxoid that failed to generate consistent 
protection in our S. pyogenes nasopharyngeal infection model (Figure 17B). Furthermore, 
SpeAN20A was incapable of activating murine T cells at all concentrations tested (Figure 
17A) and did not induce anti-SpeA IgG antibodies (Figure 17C). SAgs have been 
recognized for their ability to suppress antibody production [254,471]; however, this was 
previously reported to be primarily through T cell-mediated perforin- and Fas-FasL-
dependent B cell apoptosis [472–474]. Since SpeAN20A no longer has T cell activating 
potential (Figure 17A), this suggests an alternative, T cell-independent mechanism for 
antibody suppression, possibly mediated through direct MHC II binding. This is further 
supported by SpeATRI, which has only amino substitutions at the MHC II binding interface 
and produces a robust and protective antibody response (Figure 17B and C). Vaccination 
with toxoids containing mutations at both TCR and MHC II interacting interfaces 
(SpeATETRA and SpeAHEXA) resulted in a similar bimodal protection phenotype (Figure 
17B). The exact reasons for this phenotype have not yet been elucidated, but it is possible 
that these amino acid substitutions removed a key epitope located within the TCR binding 
site which prevented generation of SpeA-neutralizing antibodies. Alternatively, TCR 
binding site mutant SAgs may not be appropriately trafficked to B cell germinal centers 
which would prevent a robust Ab response. Further experimentation will be required to 
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elucidate the mechanism of T cell-independent antibody suppression, as well as the lack of 
protection from antibodies that can bind the wild-type toxin. However, our discovery of 
SpeATRI and its effectiveness as a vaccine against GAS further support toxoid SAgs as 
potential vaccine candidates to be used in a multi-component vaccine. 
The mammalian adaptive immune system is known to be a critical component for 
protecting the host against infection. More specifically, T lymphocytes are known to be 
crucial components, aiding in the removal of viruses and intracellular pathogens, as well 
as modulating of immune microenvironments and stimulating antibody production by B 
cells. Through extremely diverse TCRs, T cells can recognize an astonishing number of 
peptides when presented on MHC molecules. It is thus not surprising that T cells are 
beneficial to the host in numerous infection models including those involving 
Mycobacterium tuberculosis [475], Haemophilus influenza [476], Salmonella enterica 
serovar Typhimurium [477] and Listeria monocytogenes [458]. Interestingly, in the case 
of S. pyogenes, a robust nasopharyngeal infection required the presence of SAg-responsive 
T cells. Vaccination with wild-type SpeA and SEB unexpectedly protected mice from S. 
pyogenes nasopharyngeal infection without the generation of anti-SAg antibodies (Figure 
13C and D). We were able to show that this protection was due to rendering specific SAg-
targeted Vβ T cells unresponsive (Figure 14). Depleting CD4+ and CD8+ T cells via 
antibody administration was also shown to be detrimental to GAS infection of the upper 
respiratory tract (Figure 18). Interestingly, removal of CD8+ T cells alone impaired 
nasopharyngeal infection (Figure 18D); however, SAgs are able to activate both CD4+ and 
CD8+ T cells (Figure 6C), and thus we suspect that although both cells likely contribute 
to this phenotype, CD8+ T cells may be more numerically dominant within this 
environment (Figure 18C). Since we were able to detect activation of SpeA-targeted Vβ8+ 
T cells in vivo during S. pyogenes nasopharyngeal infection (Figure 9), and previous work 
from our laboratory indicates that both host expression of human MHC II (HLA-DQ8) and 
expression of SpeA are critical for S. pyogenes infection [377], this work supports that S. 
pyogenes requires Vβ-specific and functional T cells to promote upper respiratory tract 
infection. 
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This S. pyogenes T cell-dependent infection phenotype was shown to be in contrast to 
infection with S. pneumoniae, another Gram-positive, human nasopharyngeal colonizer 
that can disseminate from this site to cause a wide variety of invasive diseases 
[451,452,460]. Importantly, S. pneumoniae does not produce any known SAgs and thus its 
ability to colonize and infect the upper respiratory tract is completely independent of these 
toxins. S. pneumoniae was shown to infect HLA-DQ8 transgenic mice better than C57Bl/6 
mice (Figure 19A), however, both infection groups harbored ~5 logs of bacteria or more, 
on average, and thus it appears that the role MHC II plays in this infection model is minimal 
and not as pronounced as with S. pyogenes (Figure 8). Active immunity against S. 
pneumoniae nasopharyngeal infection has been shown to be mediated by CD4+ T cells 
[478], however, depletion of this T cell subset did not impact bacterial load at 48 hours 
(Figure 20A). This result was not unexpected, as mice were naïve to S. pneumoniae 
infection and the infection timeframe was too short to mount an adaptive immune response. 
These results demonstrate that although both organisms colonize a similar niche, their 
mechanisms for doing so appear to be very different. 
Inflammation is a hallmark of the host response to an invading pathogen and generally acts 
to recruit factors that promote the clearance of the assaulting organism. In the presence of 
functioning T cells, when S. pyogenes had high bacterial load (Figure 13C and 18D), a 
robust cytokine and chemokine response was observed in the nasopharyngeal environment 
(Figure 21B, C and Appendix 4). Conversely, when bacterial load in the murine cNT was 
decreased by SpeA or SEB vaccination (Figure 13C) or CD4+ and CD8+ T cell depletion 
(Figure 18D), the cytokine and chemokine profile mimicked that of uninfected mice 
(Figure 21A, B, C and Appendix 4). There was no significant impact on S. pneumoniae 
bacterial load upon CD4+ and CD8+ T cell depletion; however, a trend of increased CFUs 
was observed in T cell depleted mice (Figure 20A), accompanied by an enhanced cytokine 
response (Figure 21D). These results indicated that there is a consistent inflammatory 
signature when bacterial load is high. If an organism is able to avoid mucocilliary clearance 
mechanisms, its next goal is to adhere to the underlying epithelial surface [479]. This 
binding would theoretically also engage pattern recognition receptors of the innate immune 
system resulting in inflammation [480]. Since inflammatory cytokine levels were 
comparable in wild-type SAg vaccinated (SpeA and SEB), T cell-depleted (CD4 and CD8 
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together), as well as uninfected mice, this would indicate that in the absence of SAg-driven 
T cell activation, S. pyogenes cannot initiate even the earliest steps of nasopharyngeal 
colonization. Taken further, it can be hypothesized that this early inflammatory response 
is favorable for the bacteria and could provide a suitable environment for it to flourish. 
There are other examples of bacteria-generated inflammation that appear to aid in the 
establishment of infection. Neisseria gonorrhoeae has been shown to secrete the modified 
sugar heptose-1,7-bisphosphate (HBP) as a novel pathogen-associated molecular pattern 
(PAMP) that is recognized by innate immune receptors in host cells, leading to an 
inflammatory response [481–483]. All analyzed Gram-negative organisms can produce 
HBP, but Neisseria species were found to release this sugar during growth [481], 
implicating an ‘intent’ by the organism to cause this immune response. It is currently 
unknown as to why this organism in particular liberates this molecule, but it does have 
interesting implications in pathogen-intended inflammation. Lupp et al. were also able to 
show that inflammation in a murine model of infectious colitis benefitted the infecting 
bacteria by eliminating the endogenous microflora and supporting the growth of introduced 
aerobic bacteria [484]. In a model of murine chronic otitis media, nontypeable 
Haemophilus influenzae was found to persist for up to two months in a cytokine rich 
environment of IL-1β, TNF-α, IL-10 and transforming growth factor (TGF)-β. Upon 
removal of T regulatory (Treg) cells, a ~3 log reduction of bacteria was demonstrated [485]. 
Although SAgs can induce Treg cells [486,487], our data does not suggest a Treg-dependent 
phenotype as IL-10 was uniformly very low (<10 pg/mL) (Appendix 4) in all experimental 
conditions, and infection with S. pyogenes induced a prominent IL-6 and IL-17 response 
(Figure 21; Appendix 4). Therefore, our data suggests a more redundant role for CD4+ 
and CD8+ T cells. Both S. pyogenes and H. influenzae are regularly found in cases of human 
recurrent acute tonsillitis and tonsillar hypertrophy [488] and these patients are known to 
have an increase in IL-1α, IL-1β and TNF-α secreting cells in their tonsillar tissue [489]. 
Tonsillar cells from these patients re-stimulated with heat killed H. influenzae or S. 
pyogenes similarly had an increase in these, and other, Th1 cytokines [490]. These 
cytokines were also observed when the S. pyogenes bacterial load was high in the cNT of 
infected mice (control vaccinated and isotype control treated mice; Figure 21B and C). All 
124 
 
of these data suggest that certain organisms many induce an inflammatory environment 
upon infection to assist the microbe in the early stages of infection. 
A major question that has yet to be answered is what biological role do SAgs play in the 
life cycle of S. pyogenes. SAgs have been primarily associated with severe and invasive 
diseases [187], however, the high conservation and apparent functional redundancy of 
these toxins indicate that they may play a more important role in S. pyogenes biology. Our 
findings support the hypothesis that SAgs are critical factors at the early stage of 
nasopharyngeal infection. Upon introduction into the upper respiratory tract, GAS 
upregulates numerous virulence and colonization factors, including SAgs. This has been 
well documented in vivo during the early colonization phase in a non-human primate model 
of GAS pharyngitis [327]. Secreted SAgs would likely interact with T cells and APCs in 
the local lymph node environments such as the Waldeyer’s ring in humans or the NALT in 
the murine nasopharynx. This would stimulate a local inflammatory response driven by T 
lymphocyte activation, which may perform a number of crucial tasks for the bacterium 
including: suppression of innate phagocytic cell recruitment or function; expose important 
binding receptors on host cells; enhance nutrient acquisition by the pathogen; and/or inhibit 
members of the endogenous microbiota to reduce competition (Figure 22). Interestingly, 
previously published work from our laboratory has indicated a different role for SAg toxins 
during S. aureus nasopharyngeal infection. S. aureus SAg knockout strains were shown to 
have higher bacterial densities in the nasal cavity compared to wild-type counterparts, 
indicating a role for SAgs in regulating bacterial densities during colonization [491]. The 
specific benefits gained by both S. pyogenes and S. aureus manipulation of the local 
immune environment by producing SAgs remains incompletely understood, but future 
research will further elucidate the mechanistic role(s) that these toxins play in both 
organisms biology. 
This thesis provides valuable insight into the host-pathogen interaction of S. pyogenes, 
however, there are limitations to this study. First and foremost, GAS is a human-specific 
pathogen, and although our model does well represent nasopharyngeal infection, it is still 
not completely analogous to a human infection. Future studies should assess antibody-
mediated protection and T cell dependence in a more longitudinal model representing 
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colonization (vaginal colonization [389]) and/or a more human-like model (non-human 
primate [403]). Another limitation was that we were only able to test one strain of S. 
pyogenes. Future studies should analyze other isolates, such as the endemic emm1 strain 
(MGAS5005 [492] or 5448 [90,493]). Vaccine analysis focused primarily on the SAg 
SpeA. It will be important to assess other streptococcal SAgs and confirm that mutations 
to the MHC interacting interface will confer a similar protective phenotype upon 
vaccination. Lastly, many of the experiments herein used a minimal number of animals to 
reach statistical significance. Although this was due to limitations in murine colony 
breeding, it was noted that future work should run statistical power tests to determine the 
appropriate number of animals to use in each experiment and do everything possible to 
reach that number of samples per group. 
To conclude, within this work, we were able to detect expression of the SAg SpeA in vivo 
during S. pyogenes nasopharyngeal infection, further implicating the role of these toxins at 
this critical juncture of host-pathogen interaction. Numerous SpeA toxoid variants were 
also designed and generated to assess their ability to generate protective SAg-specific 
antibodies in vivo. Antibody-mediated protection was successfully demonstrated against S. 
pyogenes nasopharyngeal infection using both passive immunization and vaccination with 
a SpeA MHC II binding interface variant, SpeATRI. Vaccination of mice with wild-type 
SAgs and T cell depletion experiments were able to demonstrate that S. pyogenes requires 
responsive Vβ-specific T cells in order to infect the cNT, a phenotype to our knowledge 
that is completely unique to a bacterial pathogen. We were also able to show that in the 
presence of T cells, S. pyogenes infection correlates with a robust cytokine response that 
was completely absent when T cells are unresponsive or depleted. This implicates a T cell-
driven cytokine environment that is necessary for the establishment of infection. To our 
knowledge, this thesis presents the first use of a toxoid SAg to generate antibody-mediated 
protection against S. pyogenes nasopharyngeal infection. From this work, there is now a 
template to generate other SAg toxoids that can be used to create a potential vaccine 
containing all streptococcal SAgs, which offers a different approach to current vaccine 
strategies against S. pyogenes. Additionally, this work helps to guide the future of SAg 
research, from a toxin that causes severe disease to a tool used by bacteria to establish   
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Figure 22. Proposed mechanism of superantigen benefit to S. pyogenes. 
S. pyogenes (group A streptococcus; GAS) gains access to the nasopharynx of its host and 
quickly up-regulates virulence factors including SAgs (1). SAgs traverse the epithelium to 
the local lymph environment such as Waldery’s ring in humans or the NALT in mice (2). 
In the local lymph environment SAgs are able to activate both T cells (T) and antigen 
presenting cells (APC) via interacting with the TCR and MHC II, respectively, which leads 
to cytokine and chemokine production from both cell subset (3). Numerous bacterial 
benefits are possible from cytokine and chemokine production including: suppression of 
innate immune cell recruitment/function; exposure of binding receptors; enhanced nutrient 
acquisition; and removal of endogenous competing microflora (4). These outcomes would 
then allow the bacteria to survive and prosper in the nasopharynx. 
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infection. Analyzing SAgs from this perspective may have wide-reaching implications on 
the numerous organisms and viruses that utilize these truly unique proteins.  
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Appendices 
Appendix 1. Human ethics approval certification. 
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Appendix 2. Animal ethics approval certification. 
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Appendix 3. Vaccination with SpeAN20A/Y100A elicits an antibody-dependent bimodal 
phenotype. 
A. HLA-DR4/DQ8 mice were vaccinated with SpeAN20A/Y100A and intranasally infected 
with 108 CFU of S. pyogenes MGAS8232. Data points represent CFU from the cNT of 
individual mice 48 hours post infection. Horizontal bars represent the mean. Horizontal 
dotted line indicates limit of detection. B. Serum was collected 24 hours prior to infection 
and used to assess IgG antibody titres using ELISA (n ≥ 3). Data represented as the mean 
± SEM. Significance determined by Student’s t test (***, P < 0.001). The cNT bacterial 
load and anti-SpeA IgG titre data have already been reported (Figure 17B and C, 
respectively). 
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Appendix 4. Cytokine response from complete nasal turbinates during streptococcal 
infection after indicated treatment. 
Mice were treated with T cell depleting antibodies (CD4 [GK1.5], CD8 [YTS 169.4] or 
combination), an isotype control (LTF-2) or wild-type SAg vaccination (SpeA or SEB) or 
control (sham) and infected intranasally with either 108 CFU S. pyogenes MGAS8232 or 
107 S. pneumoniae P1121. Sacrifice occurred 48 hours later and complete nasal turbinates 
(cNT) homogenates were analyzed for multiple cytokines and chemokines (Th1-type [A]; 
Th2-type cytokines [B]; Treg cytokines [C]; Th17 cytokines [D]; chemokines [E]; or 
growth factors [F]). Data represents the mean ± SEM of cNT cytokine/chemokine 
concentration (pg mL-1) (n ≥ 3 mice per group). Significance was determined by one-way 
ANOVA with Dunnett’s multiple comparison post-hoc test (S. pyogenes) or Student’s t test 
(S. pneumoniae) (*, P < 0.05; **, P < 0.01; ***, P < 0.001). 
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